

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LURASIDONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for LURASIDONE HYDROCHLORIDE TABLETS.

LURASIDONE HYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 2010

- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-**RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS** See full prescribing information for complete boxed warning.
- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone hydrochloride tablet is not approved for the treatment of patients with dementia-related psychosis (5.1).
- Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors. (5.2).

--- INDICATIONS AND USAGE---

- Lurasidone hydrochloride is an atypical antipsychotic indicated for the treatment of:
- Schizophrenia in adults and adolescents (13 to 17 years)(1, 14.1)
- Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and
- pediatric patients (10 to 17 years) as monotherapy (1, 14.2) Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate (1, 14.2)

---DOSAGE AND ADMINISTRATION--

Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride tablets (2.3, 12.3).

Indication	Starting Dose	Recommended Dose
Schizophrenia – adults (2.1)	40 mg per day	40 mg to 160 mg per day
Schizophrenia – adolescents (13 to 17 years) (2.1)	40 mg per day	40 mg to 80 mg per day
Bipolar Depression – adults (2.2)	20 mg per day	20 mg to 120 mg per day
Bipolar Depression – pediatric patients (10 to 17 years) (2.2)	20 mg per day	20 mg to 80 mg per day

- Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day (2.4, 8.6).
- Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment (2.5, 8.7).
- Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day (2.6, 7.1)
- Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride tablets (2.6, 7.1).

FULL PRESCRIBING INFORMATION: CONTENTS*	6
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL	
THOUGHTS BEHAVIORS	-

INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION

- Schizophrenia
- Depressive Episodes Associated with Bipolar I Disorder
- Administration Information
- Dose Modifications for Renal Impairment Dose Modifications for Hepatic Impairment
- 2.5 Dose Modifications Due to Drug Interactions of CYP3A4 Inhibitors and CYP3A4 Inducers
- DOSAGE FORMS AND STRENGTHS

CONTRAINDICATIONS WARNINGS AND PRECAUTIONS

- Increased Mortality in Eldery Patients with Dementia-Related Psychosis Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis
- 5.3 5.4
- Neuroleptic Malignant Syndrome
- Tardive Dyskinesia Metabolic Changes 5.5 5.6
- 5.7 Hyperprolactinemia
- Leukopenia, Neutropenia and Agranulocytosis Orthostatic Hypotension and Syncope Falls 5.8 5.9 5.10
- 5.11 Seizures
- Potential for Cognitive and Motor Impairment Body Temperature Dysregulation 5.13 5.14
- Activation of Mania/Hypomania 5 15 Dvsphagia
- Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies

---DOSAGE FORMS AND STRENGTHS--Tablets: 20 mg, 40 mg, 60 mg, 80 mg and 120 mg (3)

- ---CONTRAINDICATIONS--· Known hypersensitivity to lurasidone hydrochloride tablets or any components in the
- formulation (4). Concomitant use with a strong CYP3A4 inhibitor (e.g., ketoconazole) (2.6, 4, 7.1). Concomitant use with a strong CYP3A4 inducer (e.g., rifampin) (2.6, 4, 7.1).

----WARNINGS AND PRECAUTIONS--

- <u>Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis</u> Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) (5.3)
- Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring (5.4).
- <u>Tardive Dyskinesia:</u> Discontinue if clinically appropriate (5.5).
- Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain (5.6)
- Hyperprolactinemia: Prolactin elevations may occur (5.7).
- Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with a preexisting low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider discontinuing lurasidone hydrochloride tablets if a clinically significant decline in WBC occurs in the absence of other causative factors (5.8).
- Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients
- with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope (5.9)

--ADVERSE REACTIONS-Commonly observed adverse reactions (incidence \geq 5% and at least twice the rate for placebo) were (6.1)

- · Adult patients with schizophrenia: somnolence, akathisia, extrapyramidal symptoms, and nausea
- · Adolescent patients (13 to 17 years) with schizophrenia: somnolence, nausea, akathisia, EPS (non-akathisia), rhinitis (80mg only), and vomiting
- · Adult patients with bipolar depression: akathisia, extrapyramidal symptoms, and somnolence
- Pediatric patients (10 to 17 years) with bipolar depression: nausea, weight increase, and insomnia

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or <u>www.fda.gov/medwatch.</u>

--- USE IN SPECIFIC POPULATIONS

· Pregnancy: May cause extrapyramidal and or/withdrawal symptoms in neonates with third trimester exposure (8.1).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide

Drugs Having Clinically Important Interactions with Lurasidone Hydrochloride

7.2 Drugs Having No Clinically Important Interactions with Lurasidone Hydrochloride USE IN SPECIFIC POPULATIONS

enesis, Mutagenesis, Impairment of Fertility

14.2 Depressive Episodes Associated with Bipolar I Disorder

* Sections or subsections omitted from the Full Prescribing Information are not listed.

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 3.

HOW SUPPLIED/STORAGE AND HANDLING

Table 3: Change in Fasting Glucose in Adult Schizophrenia Studie

PATIENT COUNSELING INFORMATION

ADVERSE REACTIONS

DRUG INTERACTIONS

Pregnancy

Lactation

Pediatric Use

Geriatric Use

Renal Impairment

Hepatic Impairment

DRUG ABUSE AND DEPENDENCE

Controlled Substance

10.1 Human Experience 10.2 Management of Overdosage

Mechanism of Action

Pharmacodynamics Pharmacokinetics

CLINICAL PHARMACOLOGY

NONCLINICAL TOXICOLOGY

CLINICAL STUDIES

7.1

8.2

8.4 8.5

8.6

8.7

OVERDOSAGE

DESCRIPTION

12.1

12.2

13.1 Carci

13

Adults

Clinical Trials Experience Postmarketing Experience

Revised: 10/2023

Table 11: Mean Change in Weight (kg) from Baseline in the Adult Monotherapy Bipolar Depression S	Study
--	-------

Lurasidone Hydrochloride Tablets

Placebo (n=151) 20 to 60 mg/day (n=143) 80 to 120 mg/day (n=147) All Patients -0.04 +0.56 +0.02 Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 60 mg/day, lurasidone hydrochloride tablets

80 to 120 mg/day, or placebo In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets as

onotherapy in the short-term and continued in the longer-term study had a mean change in weight of -0.02 kg at week 24

Adjunctive Therapy with Lithium or Valproate

Augurative inerapy mini channel vaproate Data from the adult short-term, flexible-closed, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 12. The mean change in weight gain was +0.11 kg for lurasidone hydrochloride tablets-treated patients compared to +0.16 kg for placebo-treated patients. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 3.1% for done hydrochloride tablets-treated patients and 0.3% for placebo-treated patients

Table 12: Mean Change in Weight (kg) from Baseline in the Adult Adjunctive Therapy Bipolar Depression Studies

		Lurasidone Hydrochloride Tablets 20 to 120 mg/day (n=327)
All Patients	+0.16	+0.11
Patients were randomized to flexibly dosed li	rasidone hydrochloride tablets 20 to 120 m	n/day or placebo as adjunctive therapy wit

lithium or valproate

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone hydrochloride tablets, as adjunctive therapy with either lithium or valproate in the short-term and continued in the longer-term study, had a mean change in weight of +1.28 kg at week 24 (n = 86).

Pediatric Patients (10 to 17 years) Data from the 6-week, placebo-controlled bipolar depression study in patients 10 to 17 years are presented in Table 13. The mean change in weight gain was +0.7 kg for lurasidone hydrochloride tablets-treated patients compared to +0.5 kg for placebo-treated patients. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 4.0% for lurasidone hydrochloride tablets-treated patients and 5.3% for placebo-treated patients.

Table 13: Mean Change in Weight (kg) from Baseline in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)

(n = 170)All Patients +0.5

Placebo

Pediatric Patients (6 to 17 years)

In a long-term, open-label study that enrolled pediatric patients with schizophrenia, bipolar depression, or autistic disorder from three short-term, placebo-controlled trials, 54% (378/701) received lurasidone for 104 weeks. The mean increase in weight from open-label baseline to Week 104 was 5.85 kg. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of children and adolescents by comparisons to age- and sex-matched population standards. A z-score change <0.5 SD is considered not clinically significant. In this trial, the mean change in z-score from open label baseline to Week 104 was -0.06 SD for body weight and -0.13 SD for body mass index (BMI), indicating minimal deviation from the normal curve for weight gain

5.7 Hyperprolactinemia As with other drugs that antagonize dopamine D2 receptors, lurasidone hydrochloride tablets elevates prolactin levels

Average Antices and the second sec Inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactor rine, amenorrhea gynecomastia, and impotence have been reported with prolactin-elevating compounds. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in both female and male patients [see Adverse Reactions (6)].

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent *in vitro*, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in a carcinogenicity study conducted with lurasidone in rats and mice [see Nonclinical Toxicology (13)]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Schizophrenia Adults

In short-term, placebo-controlled schizophrenia studies, the median change from baseline to endpoint in prolactin levels for Invasione hydrochloride tablets-treated patients was +0.4 ng/mL and was -1.9 ng/mL in the placebo-treated patients. The median change from baseline to endpoint for males was +0.5 ng/mL and for females was -0.2 ng/mL. Median changes for prolactin by dose are shown in Table 14.

Table 14: Median Change in Prolactin (ng/mL) from Baseline in Adult Schizophrenia Studies

		Lurasidone Hydrochloride Tablets				
	Placebo	20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day
All Patients	-1.9	-1.1	-1.4	-0.2	+3.3	+3.3
	(n=672)	(n=70)	(n=476)	(n=495)	(n=284)	(n=115)
Females	-5.1	-0.7	-4.0	-0.2	+6.7	+7.1
	(n=200)	(n=19)	(n=149)	(n=150)	(n=70)	(n=36)
Males	-1.3	-1.2	-0.7	-0.2	+3.1	+2.4
	(n=472)	(n=51)	(n=327)	(n=345)	(n=214)	(n=79)

The proportion of patients with prolactin elevations \geq 5× upper limit of normal (ULN) was 2.8% for lurasidone hydrochloride tablets-treated patients and = 1.0% for placebo-treated patients. The proportion of female patients with prolactin elevations \geq 5x ULN was 5.7% for lurasidone hydrochloride tablets-treated patients and = 2.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations \geq 5x ULN was 1.6% and 0.6% for placebo-treated male patients.

In the uncontrolled longer-term schizophrenia studies (primarily open-label extension studies), lurasidone hydrochloride tablets were associated with a median change in prolactin of -0.9 ng/mL at week 24 (n=357), -5.3 ng/mL at week 36 (n=190) and -2.2 ng/mL at week 52 (n=307).

In the short-term, placebo-controlled adolescent schizophrenia study, the median change from baseline to endpoint in prolactin The bolt start of the start become background to the start of the sta

Table 15: Median Change in Prolactin (ng/mL) from Baseline in the Adolescent Schizophrenia Stud

······	····· (·· 3 /···-)			1163063311633			U		0	2	-
	Placebo	Lurasidone Hydrochloride Tablets 40 mg/day	Lurasidone Hydrochloride Tablets 80 mg/day	Note: Figures rounded to the neares * Somnolence includes adverse	event terms:						
All Patients	+0.10 (n=103)	+0.75 (n=102)	+1.20 (n=99)	** Extrapyramidal symptoms inc disorder, hypokinesia, muscle tongue spasm, torticollis, trem	e rigidity, ocu	logyric crisi					
Females	+0.70 (n=39)	+0.60 (n=42)	+4.40 (n=33)	Dose-Related Adverse Reactions i			ies				
Males	0.00 (n=64)	+0.75 (n=60)	+1.00 (n=66)	Akathisia and extrapyramidal sym (5.6% for lurasidone hydrochlorid bydraebleride tablete 80 mg. and	de tablets 20	mg, 10.7%	6 for lurasido	one hydrochl	oride tablet	s 40 mg,	12.3% for lurasidone

5.15 Dysphagia

(5.1)]

Precautions (5.3)]

Precautions (5.16)]

twice the placebo rate

Body System of

Gastrointestinal Disorders

lervous System Disorders

Extrapyramidal Disorde

Psychiatric Disorders

otherapy)

somnolence, nausea, vomiting, diarrhea, and anxiety.

with bipolar depression) are shown in Table 20.

Body System or Organ Class

Dictionary-derived Terr

Gastrointestinal Disorders

fections and Infestati

sopharyngitis

Jrinary Tract Infection

Musculoskeletal and Connective Tissue Disorders

Nausea

Dry Mouth

miting

)iarrhea

Influenza

Bipolar Depression

valproate (n=360).

placebo rate

with bipolar depression) are shown in Table 21.

Body System or Organ Class

Gastrointestinal Disorders

fections and Infestation

Metabolism and Nutrition Disorders

Note: Figures rounded to the nearest integer

sychomotor retardation, tongue spasm, torticollis, tremor, and trismus

lausea

atique

omiting

General Disorders

sopharyngitis

Weight Increased

ncreased Appetite

Nervous System Disorder

Extrapyramidal Symptom

Psychiatric Disorders

Investigations

omnolence

stlessness

Schizophrenia

Akathisia

ary-derived Term

Note: Figures rounded to the nearest intege

Dose-Related Adverse Reactions in the Monotherapy Study

Musculoskeletal and Connective Tissue Disorders

Organ Class

Nausea

Vomiting

Dyspepsia

Back Pain

Agitation

nxiety

120 ma).

placebo rate.

Bipolar Depression (Mono

omnolence* Akathisia

alivary Hyperse

vith schizophrenia) are shown in Table 19.

6.1

Lurasidone Hydrochloride Tablets

20 to 80 mg/day (n=175)

+0.7

Clinical Trials Experience

patients had at least 52 weeks of exposure.

Pediatric Patients (10 to 17 years) In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, somnolence was reported by 11.4% (20/175) of patients treated with lurasidone hydrochloride tablets 20 to 80 mg/day compared to 5.8% (10/172) of placebo treated

5.13 Body Temperature Dysregulation Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing lurasidone hydrochloride tablets for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

In the adult bipolar depression monotherapy and adjunctive therapy (with lithium or valproate) studies, less than 1% of subjects in the lurasidone hydrochloride tablets and placebo groups developed manic or hypomanic episodes.

Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. Lurasidone

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic

medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls,

The following adverse reactions are discussed in more detail in other sections of the labeling:
 Increased Mortality in Elderly Patients with Dementia-Related Psychosis *[see Boxed Warning and Warnings and Precaution:*

Dysphagia [see Warnings and Precautions (5.15)] Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies [see Warnings and

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug

The information below is derived from an integrated clinical study database for lurasidone hydrochloride tablets consisting of 3799

adult patients exposed to one or more doses of lurasidone hydrochloride tablets for the treatment of schizophrenia, and bipolar depression in placebo-controlled studies. This experience corresponds with a total experience of 1250.9 patient-years. A total of 1106 lurasidone hydrochloride tablets-treated patients had at least 24 weeks and 371 lurasidone hydrochloride tablets-treated

Adverse events during exposure to study treatment were obtained by general inquiry and voluntarily reported adverse experiences, as well as results from physical examinations, vital signs, ECGs, weights and laboratory investigations. Adverse experiences were

recorded by clinical investigators using their own terminology. In order to provide a meaningful estimate of the proportion of

The following findings are based on the short-term, placebo-controlled premarketing adult studies for schizophrenia in which

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence > 5% and at least twice the rate of

placebo) in patients treated with lurasidone hydrochloride tablets were somnolence, akathisia, extrapyramidal symptoms, and

Adverse Reactions Associated with Discontinuation of Treatment: A total of 9.5% (143/1508) lurasidone hydrochloride tablets-treated patients and 9.3% (66/708) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone hydrochloride tablets that were at least 2% and at least

Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride Tablets-Treated Patients: Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent

and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients

Table 19: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in Adult Short-term Schizophrenia Studies

Percentage of Patients Reporting Reaction

40

Placebo (N=708) (N=71) 20

0

10

lurasidone hydrochloride tablets were administered at daily doses ranging from 20 to 120 mg (n = 331).

Lurasidone Hydrochloride Tablets

80

(%)

12

12

11

iydrochloride tablets 80 mg, and 22.0% for lurasidone hydrochloride tablets 120 mg). Akathisia was reported by 7.4% (9/121) o

hydrochloride tablets 40 mg, 11.9% for lurasidone hydrochloride tablets 80 mg, and 22.0% for lurasidone hydrochloride tablets

The following findings are based on the adult short-term, placebo-controlled premarketing study for bipolar depression in which

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence \geq 5%, in either dose group, and at least

twice the rate of placebo) in patients treated with lurasidone hydrochloride tablets were akathisia, extrapyramidal symptoms,

Adverse Reactions Associated with Discontinuation of Treatment: A total of 6.0% (20/331) lurasidone hydrochloride tablets-treated

patients and 5.4% (9/168) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone hydrochloride tablets that were at least 2% and at least twice the

Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride Tablets-Treated Patients: Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent

and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients

Table 20: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred a

Lurasidone

droch

(N = 164)

(%)

Extrapyramidal symptoms include adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramida

disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism,

Line the adult short-term, placebo-controlled study (involving lower and higher lurasidone hydrochloride tablets dose ranges) [see Clinical Studies (14.2)] the adverse reactions that occurred with a greater than 5% incidence in the patients treated with lurasidone

hydrochloride tablets in any dose group and greater than placebo in both groups were nausea (10.4%, 17.4%), somnolence (7.3%,

13.8%), akathisia (7.9%, 10.8%), and extrapyramidal symptoms (4.9%, 9.0%) for lurasidone hydrochloride tablets 20 to 60 mg/day and lurasidone hydrochloride tablets 80 to 120 mg/day, respectively.

Adjunctive Therapy with Lithium or Valproate The following findings are based on two adult short-term, placebo-controlled premarketing studies for bipolar depression in which

lurasidone hydrochloride tablets were administered at daily doses ranging from 20 to 120 mg as adjunctive therapy with lithium or

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence ≥5% and at least twice the rate of

Adverse Reactions Associated with Discontinuation of Treatment: A total of 5.8% (21/360) lurasidone hydrochloride tablets-treated

patients and 4.8% (16/334) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions

Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride Tablets-Treated Patients: Adverse

reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percen and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients

Table 21: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adult Short-term Adjunctive Therapy Bipolar Depression Studies

Percentage of Patients Reporting Reaction

Lurasidone Hydrochloride Tablets

20 to 120 mg/day

(N=360)

(%)

14

associated with discontinuation in subjects treated with lurasidone hydrochloride tablets that were at least 2% and at least twice the

20 to 60 mg/day

Percentage of Patients Reporting Reaction

Tablets

(%)

14

(N=167)

Lurasidone

udrochloride

80 to 120 mg/day

All

Lurasidon

Tablets

(%)

(N=331)

Hvdrochloride

Greater Incidence than in the Placebo-Treated Patients in the Adult Short-term Monotherapy Bipolar Depression Study

(N = 168)

<1

psychomotor retardation, tongue spasm, torticollis, tremor, and trismus Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and som

placebo) in subjects treated with lurasidone hydrochloride tablets were akathisia and somnolence

(N=334)

(%)

patients receiving 160 mg/day. Akathisia occurred in 3.0% of subjects receiving placebo. The frequency of extrapyramida symptoms increased with dose up to 120 mg/day (5.6% for lurasidone hydrochloride tablets 20 mg, 11.5% for lurasidone

mg/day mg/day (N=487) (N=538)

120

(%)

22

mg/day

(N = 291)

160

(%)

13

mg/day

(N = 121)

Lurasidon

(N=1508)

Tablets

(%)

14

lydrochlorid

individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

lurasidone hydrochloride tablets were administered at daily doses ranging from 20 to 160 mg (n=1508).

cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

hydrochloride tablets and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

rological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies

extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome

Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.4)]

Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.8)] Orthostatic Hypotension and Syncope [see Warnings and Precautions (5.9)]

Seizures [see Warnings and Precautions (5.11)] Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.12)] Body Temperature Dysregulation [see Warnings and Precautions (5.13)] Activation of Mania/Hypomania [see Warnings and Precautions (5.14)]

Tardive Dyskinesia [see Warnings and Precautions (5.5)] Metabolic Changes [see Warnings and Precautions (5.6)]

Hyperprolactinemia (see Warnings and Precautions (5, 7))

Falls [see Warnings and Precautions (5.10)]

5.14 Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. Monitor patients for the emergence of such episodes.

ADVERSE REACTIONS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death Lurasidone hydrochloride tablet is not approved for the treatment of patients with dementia-related psychosis [see

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED

PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

Suicidal Thoughts and Behaviors

FULL PRESCRIBING INFORMATION

Survival moving and beneficial to be a survival straight of the survival state of the survival straight of the survival state of the survival studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.2)].

INDICATIONS AND USAGE

Lurasidone hydrochloride tablet is indicated for

- Treatment of adult and adolescent natients (13 to 17 years) with schizonbrenia [see Clinical Studies (14.1)]
- Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar disorder (bipolar depression) [see Clinical Studies (14.2)]. Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder
- (bipolar depression) [see Clinical Studies (14.2)]

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

2 DOSAGE AND ADMINISTRATION

2.1 Schizophrenia

Adults The recommended starting dose of lurasidone hydrochloride tablets is 40 mg once daily. Initial dose titration is not required Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 160 mg per day [see Clinical

Studies (14.1)]. The maximum recommended dose is 160 mg per day.

Adolescents (13 to 17 years)

Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 80 mg per day [see Clinical] Studies (14, 1)]. The maximum recommended dose is 80 mg per day.

2.2 Depressive Episodes Associated with Bipolar I Disorde

Adults The recommended starting dose of lurasidone hydrochloride tablets is 20 mg given once daily as monotherapy or as adjunctive therapy with lithium or valproate. Initial dose titration is not required. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 20 mg per day to 120 mg per day as monotherapy or as adjunctive therapy with lithium or valproate [see *Clinical Studies (14.2)*. The maximum recommended dose, as monotherapy or as adjunctive therapy with lithium or valproate, is 120 mg per day. In the monotherapy study, the higher dose range (80 mg to 120 mg per day) did not provide additional efficacy, on average, compared to the lower dose range (20 to 60 mg per day) [see Clinical Studies (14.2)].

Pediatric Patients (10 to 17 years)

The recommended starting dose of lurasidone hydrochloride tablets is 20 mg given once daily as monotherapy. Initial dose titration is not required. The dose may be increased after one week based on clinical response. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 20 mg per day to 80 mg per day as monotherapy. At the end of the clinical study, most of the patients (67%) received 20 mg or 40 mg once daily [see Clinical Studies (14.2)]. The maximum recommended dose is 80 mg per

The efficacy of lurasidone hydrochloride tablets in the treatment of mania associated with bipolar disorder has not been established

Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride tablets. Administration with food increases the AUC approximately 2-fold and increases the C_{max} approximately 3-fold. In the clinical studies, lurasidone hydrochloride tablets were administered with food [see Clinical Pharmacology (12.3)]

The effectiveness of lurasidone hydrochloride tablets for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use lurasidone hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient *[see Dosage and Administration (2.1 and converted)*] 2.2)1

2.4 Dose Modifications for Renal Impairment

Dose adjustment is recommended in moderate (creatinine clearance: 30 to <50 mL/min) and severe renal impairment (creatinine clearance <30 mL/min) patients. The recommended starting dose is 20 mg per day. The dose in these patients should not exceed 80 mg per day [see Use in Specific Populations (8.6)].

2.5 Dose Modifications for Hepatic Impairment

Dose adjustment is recommended in moderate (Child-Pugh Score = 7 to 9) and severe hepatic impairment (Child-Pugh Score = 10 to 15) patients. The recommended starting dose is 20 mg per day. The dose in moderate hepatie impairment patients should not exceed 80 mg per day and the dose in severe hepatic impairment patients should not exceed 40 per mg/day [see Use in Specific Populations (8.7)]

2.6 Dose Modifications Due to Drug Interactions of CYP3A4 Inhibitors and CYP3A4 Inducers

Concomitant Use with CYP3A4 Inhibitors Lurasidone hydrochloride tablets should not be used concomitantly with a strong CYP3A4 inhibitor (e.g., ketoconazole, nycin, ritonavir, voriconazole, mibefradil, etc.) [see Contraindications (4)]

If lurasidone hydrochloride tablets are being prescribed and a moderate CYP3A4 inhibitor (e.g. diltiazem, atazanavir, erythromycir flucination by recent the transmission of the thrange of the transmission of the trans therapy, the recommended starting dose of lurasidone hydrochloride tablets is 20 mg per day, and the maximum recommended dose of lurasidone hydrochloride tablets is 80 mg per day [see Contraindications (4), Drug Interactions (7.1)].

Grapefruit and grapefruit juice should be avoided in patients taking lurasidone hydrochloride tablets, since these may inhibit CYP3A4 and alter lurasidone hydrochloride concentrations [see Drug Interactions (7.1)].

Concomitant Use with CYP3A4 Inducers

Lurasidone hydrochloride tablets should not be used concomitantly with a strong CYP3A4 inducer (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4); Drug Interactions (7.1)]. If lurasidone hydrochloride tablets are used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the lurasidone hydrochloride tablets dose after chronic treatment (7 days or more) with the CYP3A4 inducer.

DOSAGE FORMS AND STRENGTHS

Lurasidone hydrochloride tablets are available in the following shape and color (Table 1) with respective one-sided debossing.

Table 1: Lurasidone Hydrochloride Tablet Presentations

Tablet Strength	Tablet Color/Shape	Tablet Markings
20 mg	white to off-white round	578
40 mg	white to off-white round	684
60 mg	white to off white modified capsule	639
80 mg	pale green oval	685
120 mg	white to off-white oval	579

CONTRAINDICATIONS

Known hypersensitivity to lurasidone hydrochloride or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)]. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) /see Drug Interactions

Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)].

WARNINGS AND PRECAUTIONS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 Placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6- to 1.7-times the risk of death in placebo-controlled trials. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning, Warnings and Precautions (5.3)].

5.2 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in pediatric and vound adult patients was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo nces in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 2.

No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to

	Placebo	20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day
		Me	ean Change fror	n Baseline (mg	/dL)	
	n=680	n=71	n=478	n=508	n=283	n=113
Serum Glucose	-0.0	-0.6	+2.6	-0.4	+2.5	+2.5
		Proportio	n of Patients w	ith Shifts to \geq	126 mg/dL	
Serum Glucose $(\geq 126 \text{ mg/dL})$	8.3% (52/628)	11.7% (7/60)	12.7% (57/449)	6.8% (32/472)	10.0% (26/260)	5.6% (6/108)

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone hydrochloride tablets were associated with a mean change in glucose of +1.8 mg/dL at week 24 (n=355), +0.8 mg/dL at week 36 (n=299) and $\frac{1}{2} \text{ mg/sL}$ as the state of the state o +2.3 mg/dL at week 52 (n=307).

In studies of adolescents and adults with schizophrenia, changes in fasting glucose were similar. In the short-term, placebu controlled study of adolescents, fasting serum glucose mean values were -1.3 mg/dL for placebo (n=95), +0.1 mg/dL for 40 mg/day (n=90), and +1.8 mg/dL for 80 mg/day (n=92).

Bipolar Depression Adults

Data from the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study are presented in Table 4

Table 4: Change in Fasting Glucose in the Adult Monotherapy Bipolar Depression Study

		Lurasidone Hyd	Irochloride Tablets
	Placebo	20 to 60 mg/day	80 to 120 mg/day
•	Mean Chang	e from Baseline (mg/dL)	
	n=148	n=140	n=143
Serum Glucose	+1.8	-0.8	+1.8
	Proportion of Patier	ts with Shifts to \geq 126 mg/dL	
Serum Glucose	4.3%	2.2%	6.4%
(≥ 126 mg/dL)	(6/141)	(3/138)	(9/141)

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 60 mg/day, lurasidone hydrochloride tablets 80 to 120 mg/day, or placebo

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets as monotherapy in the short-term study and continued in the longer-term study, had a mean change in glucose of + 1.2 mg/dL at week 24(n=129)

Adjunctive Therapy with Lithium or Valproate Data from the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 5.

Table 5: Change in Fasting Glucose in the Adult Adjunctive Therapy Bipolar Depression Studies

	Placebo	Lurasidone Hydrochloride Tablets 20 to 120 mg/day
	Mean Change from Baselin	ie (mg/dL)
	n=302	n=319
Serum Glucose	-0.9	+1.2
	Proportion of Patients with	Shifts to \geq 126 mg/dL
Serum Glucose (≥ 126 mg/dL)	1.0% (3/290)	1.3% (4/316)

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mear change in glucose of +1.7 mg/dL at week 24 (n = 88).

Pediatric Patients (10 to 17 years)

In studies of pediatric patients 10 to 17 years and adults with bipolar depression, changes in fasting glucose were similar In the 6-week, placebo-controlled study of pediatric patients with bipolar depression, mean change in fasting glucose was +1.6 mg/dL for lurasidone hydrochloride tablets 20 to 80 mg/day (n=145) and -0.5 mg/dL for placebo (n=145).

atric Patients (6 to 17 years)

In a 104-week, open-label study in pediatric patients with schizophrenia, bipolar depression, or autistic disorder, 7 % of patients with a normal baseline fasting glucose experienced a shift to high at endpoint while taking lurasidone.

Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Schizophreni

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 6.

Table 6: Change in Fasting Lipids in Adult Schizophrenia Studies

		Lurasidone Hydrochioride Tablets				
	Placebo	20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day
			Mean Change	from Baseline (ı	mg/dL)	
	n=660	n=71	n=466	n=499	n=268	n=115
Total Cholesterol	-5.8	-12.3	-5.7	-6.2	-3.8	-6.9
friglycerides	-13.4	-29.1	-5.1	-13.0	-3.1	-10.6
			Proportion o	f Patients with S	hifts	
otal Cholesterol ≥ 240 mg/dL)	5.3% (30/571)	13.8% (8/58)	6.2% (25/402)	5.3% (23/434)	3.8% (9/238)	4.0% (4/101)
riglycerides ≥ 200 mg/dL)	10.1% (53/526)	14.3% (7/49)	10.8% (41/379)	6.3% (25/400)	10.5% (22/209)	7.0% (7/100)

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone hydrod were associated with a mean change in total cholesterol and triglycerides of -3.8 (n=356) and -15.1 (n=357) mg/dL at week 24, -3.1 (n=303) and -4.8 (n=303) mg/dL at week 36 and -2.5 (n=307) and -6.9 (n=307) mg/dL at week 52, respective

Adolescents In the adolescent short-term placebo-controlled study fasting serum cholesterol mean values were -9.6 mg/dl for placebo (n=95), -4.4 mg/dL for 40 mg/day (n=89), and +1.6 mg/dL for 80 mg/day (n=92), and fasting serum triglycent were +0.1 mg/dL for placebo (n=95), -0.6 mg/dL for 40 mg/day (n=89), and +8.5 mg/dL for 80 mg/day (n=92).

Bipolar Depression Adults

80 to 120 mg/day, or placebo

Monotherapy Data from the adult short-term, flexible-dosed, placebo-controlled, monotherapy bipolar depression study are presented in Table 7

Table 7

		Lurasidone Hyd	Irochloride Tablets
	Placebo	20 to 60 mg/day	80 to 120 mg/day
		Mean Change from Baseline (m	ıg/dL)
	n=147	n=140	n=144
Total cholesterol	-3.2	+1.2	-4.6
Triglycerides	+6.0	+5.6	+0.4
		Proportion of Patients with Sh	ifts
Total cholesterol (≥ 240 mg/dL)	4.2% (5/118)	4.4% (5/113)	4.4% (5/114)
Triglycerides $(> 200 \text{ mg/dL})$	4.8%	10.1%	9.8%

The proportion of patients with prolactin elevations \geq 5x ULN was 0.5% for lurasidone hydrochloride tablets-treated patients and 1.0% for placebo-treated patients. The proportion of female patients with prolactin elevations >5x ULN was 1.3% for lurasidone hydrochloride tablets-treated patients and 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations \geq 5x ULN was 0% for lurasidone hydrochloride tablets treated patients and 1.6% for placebo-treated male patients.

Bipolar Depression Adults

Monotherapy

The median change from baseline to endpoint in prolactin levels in the adult short-term flexible-dosed placebo-controlled and 80 to 120 mg/day, respectively compared to +0.3 ng/mL with placebo-treated patients. The median change from baseline to 60 mg/day endpoint for males was +1.5 ng/mL and for females was +3.1 ng/mL. Median changes for prolactin by dose range are shown in Table 16

Table 16: Median Change in Prolactin (ng/mL) from Baseline in the Adult Monotherapy Bipolar Depression Study

r			Lurasidone Hydrochloride Tablets		
		Placebo	20 to 60 mg/day	80 to 120 mg/day	
	All Patients	+0.3 (n=147)	+1.7 (n=140)	+3.5 (n=144)	
	Females	0.0 (n=82)	+1.8 (n=78)	+5.3 (n=88)	
	Males	+0.4 (n=65)	+1.2 (n=62)	+1.9 (n=56)	

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 60 mg/day, lurasidone hydrochloride tablets 80 to 120 mg/day, or placebo

The proportion of patients with prolactin elevations \geq 5x upper limit of normal (ULN) was 0.4% for lurasidone hydrochloride tablets of normal (ULN) was 0.4% for lurasidone hydrochlori treated patients and 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations \geq 5x ULN was 0.6% for lurasidone hydrochloride tablets-treated patients and 0% for placebo-treated female patients. The proportion of male batients with prolactin elevations \geq 5x ULN was 0% and 0% for placebo-treated male patients

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone hydrochloride tablets as monotherapy in the short-term and continued in the longer-term study, had a median change in prolactin of -1.15 ng/mL at week 24 (n=130).

Adjunctive Therapy with Lithium or Valproate

The median change from baseline to endpoint in prolactin levels, in the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies was +2.8 ng/mL with lurasidone hydrochloride tablets 20 to 120 mg/day compared to 0.0 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +2.4 ng/mL and for females was +3.2 ng/mL. Median changes for prolactin across the dose range are shown in Table 17.

Table 17: Median Change in Prolactin (ng/mL) from Baseline in the Adult Adjunctive Therapy Bipolar Depression Studies

	[Lurasidone Hydrochloride Tablets		Disasta	1	Musculoskeletal and Conne
			Placebo	20 to 120 mg/day		Back Pain	
ablets	Ī	All Dulla de	0.0	+2.8	1	Nervous System Disorders	
		All Patients	(n=301)	(n=321)		Extrapyramidal Symptoms*	
	[Females	+0.4	+3.2		Akathisia	
	ļ	10111100	(n=156)	(n=162)		Somnolence**	
		Males	-0.1 (n=145)	+2.4 (n=159)		Psychiatric Disorders	
	L		(11-110)	(1-100)	1	Anxiety	

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

The proportion of patients with prolactin elevations ≥5x upper limit of normal (ULN) was 0.0% for lurasidone hydrochl treated patients and 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations \geq 5x ULN was 0% oride tablets-treated patients and 0% for placebo-treated female patients. The proportion of male patients for lurasidone hydroc with prolactin elevations \geq 5x ULN was 0% and 0% for placebo-treated male pat

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone hydrochloride tablets, as adjunctive therapy with either lithium or valproate, in the short-term and continued in the longer-term study, had a median change in prolactin of -2.9 ng/mL at week 24 (n=88).

Pediatric Patients (10 to 17 years)

n the 6-week, placebo-controlled bipolar depression study with pediatric patients 10 to 17 years, the median change from baselin to endpoint in prolactin levels for lurasidone hydrochloride tablets-treated patients was +1.10 ng/mL and was +0.50 ng/mL for nlacebo-treated patients. For lurasidone hydrochloride tablets-treated patients, the median change from baseline to endpoint for nales was +0.85 ng/mL and for females was +2.50 ng/mL. Median changes for prolactin are shown in Table 18.

Table 18: Median Change in Prolactin (ng/mL) from Baseline in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)

	Placebo	Lurasidone Hydrochloride Tablets 20 to 80 mg/day
All Patients	+0.50 (n=157)	+1.10 (n=165)
Females	+0.55 (n=78)	+2.50 (n=83)
Males	+0.50 (n=79)	+0.85 (n=82)

The proportion of patients with prolactin elevations \geq 5x ULN was 0% for lurasidone hydrochloride tablets-treated patients and 0.6% for placebo-treated patients. The proportion of female patients with prolactin elevations \geq 5x ULN was 0% for lurasidone hydrochloride tablets-treated patients and 1.3% for placebo-treated female patients. No male patients in the placebo or lurasidone hydrochloride tablets treatment groups had prolactin elevations \geq 5x ULN.

5.8 Leukopenia, Neutropenia and Agranulocytosis

lurasidone hydrochloride tablets and have their WBC followed until recovery.

using a lower starting dose and slower titration, and monitor orthostatic vital signs

been reported with other agents in the class

5.9 Orthostatic Hypotension and Syncope

Pediatric Patients (6 to 17 years) In a 104-week, open-label study of pediatric patients with schizophrenia, bipolar depression, or autistic disorder, the median changes from baseline to endpoint in serum prolactin levels were -0.20 ng/mL (all patients), -0.30 ng/mL (females), and -0.05 ng/mL (males). The proportions of patients with a markedly high prolactin level (≥5 times the upper limit of normal) at any time during open-label treatment were 2% (all patients), 3% (females), and 1% (males).

verse events amono females in this trial that are potentially prolactin-related include galactorrhea (0.6%). Among male patients i this study, decreased libido was reported in one patient (0.2%) and there were no reports of impotence, gynecomastia, or

Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has

Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count (WBC) and history of drug-induced

leukopenia/neutropenia. Patients with a preexisting low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and lurasidone hydrochloride tablets should be discontinued at the first sign of decline in WBC, in the absence of other causative factors.

Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count < 1000/mm³) should discontinue

Lurasidone hydrochloride tablets may cause orthostatic hypotension and syncope, perhaps due to its a1-adrenergic receptor

antagonism. Associated adverse reactions can include dizziness, lightheadedness, tachycardia, and bradycardia. Generally, these

analysinani. Associated average reactions can include buziness, injine adeliness, and include buziness in the second second a content and units of the second second according to the second se

antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction

abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naïve. In such patients, consider

Orthostatic hypotension, as assessed by vital sign measurement, was defined by the following vital sign changes: $\geq 20 \text{ mm Hg}$

decrease in systolic blood pressure and \geq 10 bpm increase in pulse from sitting to standing or supine to standing or

Table 2: Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients

Age Range	Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1000 Patients Treated
	Increases Compared to Placebo
<18	14 additional patients
18 to 24	5 additional patients
	Decreases Compared to Placebo
25 to 64	1 fewer patient
≥65	6 fewer patients

It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression

Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing lurasidone hydrochloride tablets, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

5.3 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities compared to placebo-treated subjects. Lurasidone hydrochloride tablets are not approved for the treatment of patients with ntia-related psychosis [see Boxed Warning, Warnings and Precautions (5.1)]

5.4 Neurolentic Malignant Syndrome

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including lurasidone hydrochloride tablets. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

If NMS is suspected, immediately discontinue lurasidone hydrochloride tablets and provide intensive symptomatic treatment and monitoring.

5.5 Tardive Dvskinesia

Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment

The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, how may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppr ion has upon the long-term course of the syndrome is unknown

Given these considerations, lurasidone hydrochloride tablets should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antiosychotic treatment should generally be reserved for patients who suffer from a chronic illices that (1) is known to respond to antipsycholic treatment should generally be reserved to patients who some or spond to antipsycholic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient on lurasidone hydrochloride tablets, drug discontinuation should b considered. However, some patients may require treatment with lurasidone hydrochloride tablets despite the presence of the syndrome

5.6 Metabolic Changes

Atvoical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk These metabolic changes include hyperplycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperalycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of hyperglycemia-related adverse events in patients treated with the atypical antipsychotics.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 60 mg/day, lurasidone hydrochloride tablets

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets as monotherapy in the short-term and continued in the longer-term study had a mean change in total cholesterol and triglycerides of -0.5 mg/dL (n=130) and -1.0 mg/dL (n=130) at week 24, respectively.

Adjunctive Therapy with Lithium or Valproate

Data from the adult short-term, flexible-dosed, placebo-controlled, adjunctive therapy bipolar depression studies are presented in Table 8

Table 8: Change in Fasting Lipids in the Adult Adjunctive Therapy Bipolar Depression Studies

	Placebo	Lurasidone Hydrochloride Tablets 20 to 120 mg/day			
	Mean Change from Baseline (mg/dL)				
	n=303	n=321			
Total cholesterol	-2.9	-3.1			
Triglycerides	-4.6	+4.6			
	Proportion of Patients with Shifts				
Total cholesterol (\geq 240 mg/dL)	5.7% (15/263)	5.4% (15/276)			
Triglycerides (\geq 200 mg/dL)	8.6% (21/243)	10.8% (28/260)			

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets, as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in total cholesterol and triglycerides of -0.9 (n=88) and +5.3 (n=88) mo/dL at week 24, respectively.

atric Patients (10 to 17 years)

In the 6-week, placebo-controlled bipolar depression study with pediatric patients 10 to 17 years, mean change in fasting cholesterol was -6.3 mg/dL for lurasidone hydrochloride tablets 20 to 80 mg/day (n=144) and 1.4 mg/dL for placebo (n=145), and mean change in fasting triglyceride was -7.6 mg/dL for lurasidone hydrochloride tablets 20 to 80 mg/day (n=144) and +5.9 mg/dL for placebo (n=145).

Pediatric Patients (6 to 17 years) In a 104-week, open-label study of pediatric patients with schizophrenia, bipolar depression, or autistic disorder, shifts in baseline fasting cholesterol from normal to high at endpoint were reported in 12% (total cholesterol), 3% (LDL cholesterol), and shifts in baseline from normal to low were reported in 27% (HDL cholesterol) of patients taking lurasidone. Of patients with normal baseline fasting triglycerides, 12% experienced shifts to high

Weight Gain

Weight gain has been observed with atvoical antipsychotic use. Clinical monitoring of weight is recommended.

Schizophrenia Adults

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 9. The mean weight gain was Found value from some reality processory of the second se second sec Studies (14.1)], respectively. The proportion of patients with $a \ge 7\%$ increase in body weight (at Endpoint) was 4.8% for lurasidone ride tablets-treated patients and 3.3% for placebo-treated patients.

Table 9: Mean Change in Weight (kg) from Baseline in Adult Schizophrenia Studies

			Lurasidone Hydrochloride Tablets						
	Placebo (n=696)	20 mg/day (n=71)	40 mg/day (n=484)	80 mg/day (n=526)	120 mg/day (n=291)	160 mg/day (n=114)			
All Patients	-0.02	-0.15	+0.22	+0.54	+0.68	+0.60			

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone hydrochloride tablets ere associated with a mean change in weight of -0.69 kg at week 24 (n=755), -0.59 kg at week 36 (n=443) and -0.73 kg at week

Data from the short-term, placebo-controlled adolescent schizophrenia study are presented in Table 10. The mean change in weight gain was +0.5 kg for lurasidone hydrochloride tablets-treated patients compared to +0.2 kg for placebo-treated patients. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 3.3% for lurasidone hydrochloride tablets-treated natients and 4.5% for placebo-treated patients

Table 10: Mean Change in Weight (kg) from Baseline in the Adolescent Schizophrenia Study

		Lurasidone ł	lydrochloride Tablets
	Placebo (n=111)	40 mg/day (n=109)	80 mg/day (n=104)
All Patients	+0.2	+0.3	+0.7

Bipolar Depression Adults

Data from the adult short-term. flexible-dosed. placebo-controlled monotherapy bipplar depression study are presented in Table The mean change in weight gain was 0.28 kg for lurasidone hydrochloride tables treated patients compared to -0.04 kg for placebo-treated patients. The proportion of patients with a $\geq 7\%$ increase in body weight (at Endpoint) was 2.4% for lurasidone hydrochloride tables treated patients. d to -0.04 kg foi hydrochloride tablets-treated patients and 0.7% for placebo-treated patients.

The incidence of orthostatic hypotension and syncope reported as adverse events from short-term, placebo-controlled [0.3% (5/1508), 0.1% (1/708)] and syncope [0.1% (2/1508), 0% (0/708)].

In short-term schizophrenia clinical studies, orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.8% with lurasidone hydrochloride tablets 40 mg, 2.1% with lurasidone hydrochloride tablets 80 mg, 1.7% with lurasidone hydrochloride tablets 120 mg and 0.8% with lurasidone hydrochloride tablets 160 mg compared to 0.7% with placebo

Schizophrenia

Adults

The incidence of orthostatic hypotension reported as adverse events from the short-term, placebo-controlled adolescent schizophrenia study was 0.5% (1/214) in lurasidone hydrochloride tablets-treated patients and 0% (0/112) in placebo-treated patients. No syncope event was reported

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0% with lurasidone hydrochloride tablets 40 mg and 2.9% with lurasidone hydrochloride tablets 80 mg, compared to 1.8% with placebo.

Bipolar Depression

Adults

In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, there were no reported adverse events of orthostatic hypotension and syncope.

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.6% with lurasidone hydrochloride tablets 20 to 60 mg and 0.6% with lurasidone hydrochloride tablets 80 to 120 mg compared to 0% with placebo.

Adjunctive Therapy with Lithium or Valproate

In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression therapy studies, there were no reported adverse events of orthostatic hypotension and syncope. Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with lurasidone hydrochloride tablets 20 to 120 mg compared to 0.9% with placebo

Pediatric Patients (10 to 17 years) In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, there were no reported adverse events of orthostatic hypotension or syncope

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with lurasidone hydrochloride tablets 20 to 80 mg/day, compared to 0.6% with placebo.

5.10 Falls

Lurasidone hydrochloride tablets may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and consequently fractures or other injuries. For natients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-terr antipsychotic therapy.

5.11 Seizures

As with other antipsychotic drugs, lurasidone hydrochloride tablets should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

In adult short-term, placebo-controlled schizophrenia studies, seizures/convulsions occurred in 0.1% (2/1508) of patients treated with lurasidone hydrochloride tablets compared to 0.1% (1/708) placebo-treated patients.

Bipolar Depression

n the adult and pediatric 6-week, flexible-dose, placebo-controlled monotherapy bipolar depression studies, no patients experienced seizures/convulsions

Adjunctive Therany with Lithium or Valoroate

In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, no patient experienced seizures/convulsions.

5.12 Potential for Cognitive and Motor Impairment Lurasidone hydrochloride tablets, like other antipsychotics, has the potential to impair judgment, thinking or motor skills. Cautior patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with lurasidone hydrochloride tablets does not affect them adversely.

In clinical studies with lurasidone hydrochloride tablets, somnolence included; hypersomnia, hypersomnolence, sedation and

Schizophrenia Adults

In short-term, placebo-controlled schizophrenia studies, somnolence was reported by 17.0% (256/1508) of patients treated with In sind real m, praceocontonica solucione in a sources, sommonice was reported by 17.20 (200 1000) on patients treated with Invasione hydrochloride tablets (15.5% lurasione hydrochloride tablets 20 mg, 15.6% lurasidone hydrochloride tablets 40 mg, 15.2% lurasidone hydrochloride tablets (15.5% lurasidone hydrochloride tablets 20 mg, 26.5% lurasidone hydrochloride tablets 120 mg and 8.3% lurasidone hydrochloride tablets 40 mg, 26.5% lurasidone hydrochloride tablets 120 mg and 8.3% lurasidone hydrochloride tablets 40 mg, 26.5% lurasidone hydrochloride tablets 120 mg and 8.3% lurasidone hydrochloride tablets 40 mg, 26.5% lurasidone hydrochloride tablets 40 mg, tablets 160 mg/day) compared to 7.1% (50/708) of placebo patients.

In the short-term, placebo-controlled adolescent schizophrenia study, somnolence was reported by 14.5% (31/214) of patients treated with lurasidone hydrochloride tablets (15.5% lurasidone hydrochloride tablets 40 mg and 13.5% lurasidone hydrochloride tablets 80 mg,/day) compared to 7.1% (8/112) of placebo patients.

Bipolar Depression Adults

Nonotherapy

In the adult short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, somnolence was reported by 7.3% (12/164) and 13.8% (23/167) with lurasidone hydrochloride tablets 20 to 60 mg and 80 to 120 mg, respectively compared to 6.5% (11/168) of placebo pati

Adjunctive Therapy with Lithium or Valproate

In the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies, somnolence was reported by 11.4% (41/360) of patients treated with lurasidone hydrochloride tablets 20 to 120 mg compared to 5.1% (17/334) of

<u>Commonly Observed Adverse Reactions</u>: The most common adverse reactions (incidence ≥5% and at least twice the rate of placebo) in adolescent patients (13 to 17 years) treated with Jurasidone hydrochloride tablets were somnolence, nausea, akathisia, extrapyramidal symptoms (non-akathisia, 40mg only), vomiting, and rhinorrhea/rhinitis (80mg only).

The following findings are based on the short-term, placebo-controlled adolescent study for schizophrenia in which lurasidone hydrochloride tablets were administered at daily doses ranging from 40 (N=110) to 80 mg (N=104).

Extrapyramidal symptoms include adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyrar

** Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence

disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism,

Adverse Reactions Associated with Discontinuation of Treatment: The incidence of discontinuation due to adverse reactions e hydrochloride tablets- and placebo-treated adolescent patients (13 to 17 years) was 4% and 8%, respectively.

<u>Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride Tablets-Treated Patients:</u> Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6-weeks in adolescent patients with schizophrenia) are shown in Table 22

Table 22: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adolescent Short-term Schizophrenia Study

	Percentage of	Percentage of Patients Reporting Reaction						
Body System or Organ Class Dictionary-derived Term	Placebo (N=112)	Lurasidone Hydrochloride Tablets 40 mg/day (N=110)	Lurasidone Hydrochloride Tablets 80 mg/day (N=104)	All Lurasidone Hydrochloride Tablets (N=214)				
Gastrointestinal Disorders								
Nausea	3	13	14	14				
Vomiting	2	8	6	8				
Diarrhea	1	3	5	4				
Dry Mouth	0	2	3	2				
Infections and Infestations								
Viral Infection**	6	11	10	10				
Rhinitis	2	<1	8	4				
Oropharyngeal pain	0	<1	3	2				
Tachycardia	0	0	3	1				
Nervous System Disorders								
Somnolence*	7	15	13	15				
Akathisia	2	9	9	9				
Dizziness	1	5	5	5				

Note: Figures rounded to the nearest integer

olence includes adverse event terms: hypersomnia, sedation, and somnolence

- Viral Infection includes adverse event terms: nasopharyngitis, influenza, viral infection, upper respiratory tract infection * Rhinitis incudes adverse event terms: rhinitis, allergic rhinitis, rhinorrhea, and nasal congestior

Pediatric Patients (10 to 17 years)

Extrapyramidal Symptoms**

Bipolar Depression The following findings are based on the 6-week, placebo-controlled study for bipolar depression in pediatric patients 10 to 17 years in which lurasidone hydrochloride tablets were administered at daily doses ranging from 20 to 80 mg (N = 175).

<u>Commonly Observed Adverse Reactions</u>: The most common adverse reactions (incidence \geq 5%, and at least twice the rate of placebo) in pediatric patients (10 to 17 years) treated with lurasidone hydrochloride tablets were nausea, weight increase, and

Adverse Reactions Associated with Discontinuation of Treatment: The incidence of discontinuation due to adverse reactions ets- and placebo-treated pediatric patients 10 to 17 years was 2% and 2%, respectively

Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride Tablets-Treated Patients. Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in pediatric patients with bipolar depression) are shown in Table 23.

Table 23: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the 6-Week Bipolar Depression Study in Pediatric Patients (10 to 17 years)

	Percentage of Pat	ients Reporting Reaction
Body System or Organ Class Dictionary-derived Term	Placebo (N=172)	Lurasidone Hydrochloride Tablets 20 to 80 mg/day (N=175)
Gastrointestinal Disorders		
Vausea	6	16
/omiting	4	6
Abdominal Pain Upper	2	3
Diarrhea	2	3
Abdominal Pain	1	3
General Disorders And Administration Site Condi	tions	
Fatigue	2	3
nvestigations		
Weight Increased	2	7
Metabolism and Nutrition Disorders	-	
Decreased Appetite	2	4
Nervous System Disorders		
Somnolence*	6	11

Dizziness	5	6	
Psychiatric Disorders			
Insomnia	2	5	
Abnormal Dreams	2	2	
Respiratory, Thoracic and Mediastinal Disorders	•		
Oropharyngeal Pain	2	2	

Note: Figures rounded to the nearest intege

Somnolence includes adverse event terms; hypersomnia, hypersomnolence, sedation, and somnolence ** EPS includes adverse event terms: akathisia, cogwheel rigidity, dyskinesia, dystonia, hyperkinesia, joint stiffness, muscle rigidity, muscle spasms, musculoskeletal stiffness, oculogyric crisis, parkinsonism, tardive dyskinesia, and tremol

Extrapyramidal Symptoms

Adults

In the short-term, placebo-controlled schizophrenia studies, for lurasidone hydrochloride tablets-treated patients, the incidence of reported events related to extrapyramidal symptoms (EPS), excluding akathisia and restlessness, was 13.5% and 5.0% for placebo-treated patients. The incidence of akathisia for lurasidone hydrochloride tablets-treated patients was 12.9% and 3.0% for placebo-treated patients. Incidence of EPS by dose is provided in Table 24.

Table 24: Incidence of EPS Compared to Placebo in Adult Schizophrenia Studies

	Lurasidone Hydrochloride Tablets						
Adverse Event Term	Placebo (N=708) (%)	20 mg/day (N=71) (%)	40 mg/day (N=487) (%)	80 mg/day (N=538) (%)	120 mg/day (N=291) (%)	160 mg/day (N=121) (%)	
All EPS events	9	10	21	23	39	20	
All EPS events, excluding Akathisia/Restlessness	6	6	11	12	22	13	
Akathisia	3	6	11	12	22	7	
Dystonia*	<1	0	4	5	7	2	
Parkinsonism**	5	6	9	8	17	11	
Restlessness	1	1	3	1	3	2	

Note: Figures rounded to the nearest in

Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

Adolescents

In the short-term, placebo-controlled, study of schizophrenia in adolescents, the incidence of EPS. excluding events related to akathisia, for lurasidone hydrochloride tablets-treated patients was higher in the 40 mg (10%) and the 80 mg (7.7%) treatment groups vs. placebo (3.6%); and the incidence of akathisia-related events for lurasidone hydrochloride tablets-treated patients was 8.9% vs. 1.8% for placebo-treated patients. Incidence of EPS by dose is provided in Table 25.

Table 25: Incidence of EPS Compared to Placebo in the Adolescent Schizophrenia Study

	Lui	Lurasidone Hydrochloride Tablets				
Adverse Event Term	Placebo (N=112) (%)	40 mg/day (N=110) (%)	80 mg/day (N=104) (%)			
All EPS events	5	14	14			
All EPS events, excluding Akathisia/Restlessness	4	7	7			
Akathisia	2	9	9			
Parkinsonism**	<1	4	0			
Dyskinesia	<1	<1	1			
Dystonia*	0	<1	1			

Note: Figures rounded to the nearest integer

Dystonia includes adverse event terms: dystonia, trismus, oculogyric crisis, oromandibular dystonia, tongue spasm, and

Parkinsonism includes adverse event terms: bradykinesia, drooling, extrapyramidal disorder, glabellar reflex abnormal hypokinesia, parkinsonism, and psychomotor retardation

Bipolar Depression Adults

Monotheran

In the adult short-term, placebo-controlled monotherapy bipolar depression study, for lurasidone hydrochloride tablets-treated patients, the incidence of reported events related to EPS, excluding akathisia and restlessness was 6.9% and 2.4% for placebotreated patients. The incidence of akathisia for lurasidone hydrochloride tablets-treated patients was 9.4% and 2.4% for placebo treated patients. Incidence of EPS by dose groups is provided in Table 26.

Table 26: Incidence of EPS Compared to Placebo in the Adult Monotherapy Bipolar Depression Study

		Lurasidone I	Hydrochloride Tablets
Adverse Event Term	Placebo (N=168) (%)	20 to 60 mg/day (N=164) (%)	80 to 120 mg/day (N=167) (%)
All EPS events	5	12	20
All EPS events, excluding Akathisia/Restlessness	2	5	9
Akathisia	2	8	11
Dystonia*	0	0	2
Parkinsonism**	2	5	8
Restlessness	<1	0	3

Note: Figures rounded to the nearest intege

Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

Adjunctive Therapy with Lithium or Valproate

In the adult short-term, placebo-controlled adjunctive therapy bipolar depression studies, for lurasidone hydrochloride tabletstreated patients, the incidence of EPS, excluding akathisia and restlessness, was 13.9% and 8.7% for placebo. The incidence of akathisia for lurasidone hydrochloride tablets-treated patients was 10.8% and 4.8% for placebo-treated patients. Incidence of EPS

Table 27: Incidence of FPS Compared to Placeho in the Adult Adjunctive Therapy Bipolar Depression Studies

Adverse Event Term	Placebo (N=334) (%)	Lurasidone Hydrochloride Tablets 20 to 120 mg/day (N=360) (%)
All EPS events	13	24
All EPS events, excluding Akathisia/Restlessness	9	14
Akathisia	5	11
Dystonia*	<1	1
Parkinsonism**	8	13
Restlessness	<1	4

Note: Figures rounded to the nearest intege

Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

ot been conducted to assess the presence of lurasidone in human milk, the effects on the breas Lactation stud

Table 33: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Bipolar Depression Study in

Ε

35

Interacting drug PK

Strong CYP3A4 Inhibitor

Moderate CYP3A4 Inhibitor

Strong CYP3A4 Inducer

Rifampin 600 mg/day

Lithium 600 mg BID

Interacting drug PK

P-gp Substrates

Digoxin 0.25 mg SD

CYP3A4 Substrates

Oral Contracepti

Midazolam 5 mg SD Cmax

Fthinvl Estradiol Cma

Lithium 600 mg BID Ctrough

Studies in Specific Populations

Renal impairmen

Hepatic impairmen

Population description

13

Moderate

Severe

Mild Cmax AUC

Moderate

Severe

Gende

Females

Race

Asian* Cmax

Ketoconazole 400 mg/day Cmax

Diltiazem 240 mg/day Cmax

coadministered with lithium 300 to 2,400 mg/day or valproate 300 to 2,000 mg/day. Figure 1: Impact of Other Drugs on Lurasidone Hydrochloride Tablets Pharmacokinetics

AUC

AUC

Cmax

AUC

AUC

Cmax

Figure 2: Impact of Lurasidone Hydrochloride Tablets on Other Drugs

Cma

AUC

AUC

AUC

Cmax

AUC

-1.0

PK

AUC

AUC

AUC

Cmax

AUC

Cmax

Cmax AUC

AUC

which produced plasma levels (AUC) 14 times those in humans receiving the MRHD.

AUC

Cmax

Cmax

Mild Cmax

-0.5

The effect of intrinsic patient factors on the pharmacokinetics of lurasidone hydrochloride tablets are presented in Figure 3.

age) was generally similar to that in adults across the dose range from 40 to 160 mg, without adjusting for body weight.

Figure 3: Impact of Other Patient Factors on Lurasidone Hydrochloride Tablets Pharmacokinetics

Lurasidone hvdrochloride tablets exposure (i.e., steady-state C_{max} and AUC) in children and adolescent patients (10 to 17 years of

And the effects of lurasidone hydrochloride tablets on the exposures of other drugs are summarized in Figure 2. A population PK

analyses concluded that coadministration of lurasidone has minimal effect on lithium and valproate exposure when it is

Impact of other drugs on Lurasidone Pharmacokinetics(PK)

Fold Change and 90% Cl

Change relative to Jurasidone alone

H•H

0.0

Change relative to Interactive Drug Alone

Fold Change and 90% Cl

H**H**H

0.5

1.0

Fold Change and 90% Cl

-

Drug Interaction Studies Effects of other drugs of

effect on lurasidone exposure.

Pediatric Patients (10 to 17 years)		
Laboratory Parameter	Placebo (N=155)	Lurasidone Hydrochloride Tablets 20 to 80 mg/day (N=163)

Serum Creatinine Elevated 4.5% 6.7%

Pediatric Patients (6 to 17 years) In a 104-week, open-label study in pediatric patients with schizophrenia, bipolar depression, or autistic disorder, the mean change from baseline to Week 104 in serum creatinine was +0.07 mg/dL. In patients with a normal serum creatinine at baseline 6% experienced a shift to high at endpoint.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of lurasidone hydrochloride tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity Reactions: Urticaria, throat swelling, tongue swelling, dyspnea, and rash.

Metabolism and Nutrition Disorders: Hyponatremia

DRUG INTERACTIONS Drugs Having Clinically Important Interactions with Lurasidone Hydrochloride

Table 34: Clinically Important Drug Interactions with Lurasidone Hydrochloride

Strong CYP3A4 Inhibitors

- Concomitant use of lurasidone hydrochloride tablets with strong CYP3A4 inhibitors increased the exposure Clinica f lurasidone compared to the use of lurasidone hydrochloride tablets alone [see Clinical Pharmacology Impact: (12.3)1.
- Lurasidone hydrochloride tablets should not be used concomitantly with strong CYP3A4 inhibitors [see ntervention Contraindications (4)]. Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil Examples:

Moderate CYP3A4 Inhibitors

- Concomitant use of lurasidone hydrochloride tablets with moderate CYP3A4 inhibitors increased the Clinical xposure of lurasidone compared to the use of lurasidone hydrochloride tablets alone [see Clinical npact Pharmacology (12.3)].
- Lurasidone hydrochloride tablets dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 [see Dosage and Administration (2.6)]. tervention

Examples: Diltiazem, atazanavir, erythromycin, fluconazole, verapamil

- Strong CYP3A4 Inducers Concomitant use of lurasidone hydrochloride tablets with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone hydrochloride tablets alone [see Clinical Pharmacology Clinica Impact (12.3)].
- urasidone hydrochloride tablets should not be used concomitantly with strong CYP3A4 inducers [see nterventior Contraindications (4)]. Rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine Examples: Moderate CYP3A4 Inducers Concomitant use of lurasidone hydrochloride tablets with moderate CYP3A4 inducers decreased the linical
- exposure of lurasidone compared to the use of lurasidone hydrochloride tablets alone [see Clinical Impact: Pharmacology (12.3)]. Lurasidone hydrochloride tablets dose should be increased when used concomitantly with moderate inducers of CYP3A4 [see Dosage and Administration (2.6)]. terventior

Bosentan, efavirenz, etravirine, modafinil, nafcillir Examples:

7.2 Drugs Having No Clinically Important Interactions with Lurasidone Hydrochlorid

Based on pharmacokinetic studies, no dosage adjustment of lurasidone hydrochloride tablets is required when administered concomitantly with lithium, valproate, or substrates of P-gp or CYP3A4 [see Clinical Pharmacology (12.3)]

USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lurasidone hydrochloride tablets during pregnancy. For more information, contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/

Risk Summary

Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see *Ulinical Considerations*). There are no studies of furnaristication by deciding the set in gregnant women. The limited available data are not sufficient to inform a drug-associated risk of birth defects or miscarriage. In animal reproduction studies, no teratogenic effects were seen in pregnant rats and rabbits given lurasidone during the period of organogenesis at doses approximately 1.5- and 6-times, the maximum recommended human dose (MRHD) of 160 mg/day, respectively based on mg/m² body surface area [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations Neonatal Adverse Reactions

Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment, others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately.

Animal Data

8.2 Lactation

Pregnant rats were treated with oral lurasidone at doses of 3, 10, and 25 mg/kg/day during the period of organogenesis. These does are 0.2, 0.6, and 1.5 times the MRHD of 160 mg/day based on mg/m body ourface area. No teratogenic or embryo-fetal effects were observed up to 1.5 times the MRHD of 160 mg/day, based on mg/m².

Pregnant rabbits were treated with oral lurasidone at doses of 2 10 and 50 mg/kg/day during the period of organogenesis. These Together the decision of the decision of the decision at basis of L_2 , to, the decision m_g/m_g^2 day during the period of organized ends in the decision of decision of the decision of

Pregnant rats were treated with oral lurasidone at doses of 0.4, 2, and 10 mg/kg/day during the periods of organogenesis and lactation. These doses are 0.02, 0.1 and 0.6 times the MRHD of 160 mg/day based on mg/m². No pre- and postnatal developmental effects were observed up to 0.6 times the MRHD of 160 mg/day, based on mg/m².

<u>Risk Summary</u>

or the effects on milk production. Lurasidone is present in rat milk. The development and health benefits of breastfeeding should be or the effects of mink production. Labstoorie's present in a time. The development and mean before to breasteeding should be considered along with the mother's clinical need for lurasidone hydrochloride tablets and any potential adverse effects on the breastfed infant from lurasidone hydrochloride tablets or from the underlying maternal condition.

Lurasidone hydrochloride tablets were superior to placebo in reduction of CDRS-R total score and CGI-BP-S depression score at Week 6. The primary efficacy results are provided in Table 38.

Table 38: Primary Efficacy Results for the Study in Depressive Episodes Associated with Bipolar I Disorder (CDRS-R Total Score) in Pediatric Patients (10 to 17 years)

	Primary Efficacy Measu	re: CDRS-R	
Treatment Group	Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo-subtracted Difference ^a (95% CI)
Lurasidone hydrochloride tablets (20 to 80 mg/day)*	59.2 (8.24)	-21.0 (1.06)	-5.7 (-8.4,-3.0)
Placebo	58.6 (8.26)	-15.3 (1.08)	-

SD: standard deviation: SE: standard error: LS Mean: least-squares mean: CI: confidence interval, unadjusted for multiple

Effects of other drugs on the exposure of lurasidone are summarized in Figure 1. A population PK analyses concluded that coadministration of lithium 300 to 2,400 mg/day or valproate 300 to 2,000 mg/day with lurasidone for up to 6 weeks has minimal Difference (drug minus placebo) in least-squares mean change from baseline

Treatment group statistically significantly superior to placebo.

HOW SUPPLIED/STORAGE AND HANDLING Lurasidone hydrochloride tablets are available as follows

20 mg: White to off-white, round, film-coated tablet, debossed with '578' on one side and plain on other side.	
Bottles of 30 with Child Resistant Cap	NDC 47335-578-83
Bottles of 90 with Child Resistant Cao	NDC 47335-578-81
Bottles of 500	NDC 47335-578-13

	NDC 47335-68
Bottles of 90 with Child Resistant Cap Bottles of 500	
0000001000	
60 mg: White to off-white, modified capsule shaped, film-coated tablet,	debossed with '639' on one side and plain on other side
Delite a food the Object of the state of Object	NDC 47335-63
Bottles of 30 with Child Resistant Cap	
Bottles of 30 with Child Resistant Cap Bottles of 90 with Child Resistant Cap	

Bottles of 90 with Child Resistant Cap	NDC 47335-685-81
Bottles of 500	NDC 47335-685-13
120 mg: White to off-white, oval shaped, film-coated tablet, debossed with '579' on	one side and plain on other side
Bottles of 30 with Child Resistant Cap.	

Bottles of 500...

Store lurasidone hydrochloride tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP] Controlled Room Temperature].

.NDC 47335-579-13

PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Suicidal Thoughts and Behavior

Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider [see Boxed Warning, Warnings and

Neuroleptic Malignant Syndrome

Counsel patients about a potentially fatal adverse reaction referred to as Neuroleptic Malignant Syndrome (NMS). Advise patients, family members, or caregivers to contact healthcare provider or to report to the emergency room if they experience signs and symptoms of NMS [see Warnings and Precautions (5.4)].

Tardive Dyskinesia

Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur [see Warnings and Precautions (5.5)].

Metabolic Changes

Educate patients about the risk of metabolic changes, how to recognize symptoms of hyperglycemia and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight [see Warnings and Precautions (5.6)].

Hyperprolactinemia

Counsel patients on signs and symptoms of hyperprolactinemia that may be associated with chronic use of lurasidone hydrochloride tablets. Advise them to seek medical attention if they experience any of the following: amenorrhea or galactorrhea in females, erectile dysfunction or gynecomastia in males [see Warnings and Precautions (5.7)].

Leukopenia/Neutropenia Advise patients with a preexisting low WBC or a history of drug-induced leukopenia/neutropenia that they should have their CBC monitored while taking lurasidone hydrochloride tablets [see Warnings and Precautions (5.8)].

Warnings and Precautions (5.12)].

ctivation of Mania or Hypomania

Heat Exposure and Dehydration

Pregnancy

nsychosis

dose is changed.

Denression and other seri

suicidal thoughts or actions.

they are new, worse, or worry you: thoughts about suicide or dving

attempts to commit suicide

new or worse depression

feeling very agitated or restless

acting aggressive, being angry, or violent

other unusual changes in behavior or mood

less than 13 years of age with schizophrenia.

have or have had heart problems or stroke

have or have had high prolactin levels

hvdrochloride tablets

vitamins, and herbal supplements

How should I take lurasidone hydrochloride tablets?

nearest hospital emergency room right away.

Do not exercise too much.

Stay out of the sun.

Drink plenty of water.

high fever

tablets.

hydrochloride tabl

feel very thirsty

feel very hungry feel weak or tired

feel sick to your stomach

stiff muscles confusion

increased sweating

Problems with your metabolism such as:

need to urinate more than usual

What should I avoid while taking lurasidone hydrochloride tablets?

In hot weather, stay inside in a cool place if possible

What are the possible side effects of lurasidone hydrochloride tablets?

changes in your breathing, heart rate, and blood pressure

lone hydrochloride tablets may cause serious side effects, in

Do not wear too much clothing or heavy clothing.

hydrochloride tablets work.

provider first.

a new medicine.

have or have had seizures

pregnancy.

have or have had low or high blood pressure

have or have had low white blood cell count

have or have had kidney or liver problems

less than 10 years of age with bipolar depression

Do not take lurasidone hydrochloride tablets if you are:

for the treatment of irritability associated with autistic disorder

provider if you are not sure if you are taking any of these medicines.

have or have had high levels of total cholesterol or triglycerides

What is lurasidone hydrochloride tablets?

an extreme increase in activity and talking (mania)

Lurasidone hydrochloride tablet is a prescription medicine used: To treat people 13 years of age or older with schizophrenia.

It is not known if lurasidone hydrochloride tablets are safe and effective in children:

trouble sleeping (insomnia)

acting on dangerous impulses

new or worse irritability

(bipolar depression).

including if you:

new or worse anxiety

panic attacks

<u>Orthostatic Hypotension</u> Educate patients about the risk of orthostatic hypotension, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose [see Warnings and Precautions (5.9)].

motor vehicle, until they are reasonably certain that lurasidone hydrochloride tablets therapy does not affect them adversely [see

Advise patients and their caregivers to observe for signs of activation of mania/hypomania [see Warnings and Precautions (5.14)]

Concomitant Medication Advise patients to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, because

Advise patients that lurasidone hydrochloride tablets may cause extrapyramidal and/or withdrawal symptoms in a neonate. Advise

patients to notify their healthcare provider with a known or suspected pregnancy [see Use in Specific Populations (8.1)]. Advise

patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lurasidone hydrochloride tablets during pregnancy [see Use in Specific Populations (8.1)].

Medication Guide

(loo-RAS-i-done HYE-droe-KLOR-ide)

Tablets

Increased risk of death in elderly people with dementia-related psychosis. Medicines like lurasidone hydrochloride can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory

loss (dementia). Lurasidone hydrochloride tablet is not approved for the treatment of people with dementia-related

Increased risk of suicidal thoughts or actions in children and young adults. Antidepressant medicines may increase

suicidal thoughts or actions in some children and young adults within the first few months of treatment and when the

Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who

have (or have a family history of) depression, bipolar illness (also called manic-depressive illness), or a history of

Pay close attention to any changes, especially sudden changes in mod, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.

Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as

Call the healthcare provider right away to report new or sudden changes in mood, behavior thoughts, or feelings

Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if

Alone to treat people 10 years of age and older with depressive episodes that happen with Bipolar I Disorder (bipolar

With the medicine lithium or valproate to treat adults with depressive episodes that happen with Bipolar I Disorder

allergic to lurasidone hydrochloride or any of the ingredients in lurasidone hydrochloride tablets. See the end of this Medication Guide for a complete list of ingredients in lurasidone hydrochloride tablets.

taking certain other medicines called CYP3A4 inhibitors or inducers including ketoconazole, clarithromycin, ritonavir.

Before taking lurasidone hydrochloride tablets, tell your healthcare provider about all of your medical conditions

are pregnant or plan to become pregnant. It is not known if lurasidone hydrochloride tablets will harm your unborn baby

Talk to your healthcare provider about the risk to your unborn baby if you take lurasidone hydrochloride tablets during

Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with lurasidone

If you become pregnant during treatment with lurasidone hydrochloride tablets, talk to your healthcare provider

about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or go to http://womensmentalhealth.org/clinical and researchprograms/pregnancyregistry/. are breastfeeding or plan to breastfeed. It is not known if lurasidone hydrochloride passes into your breast milk. Talk to

your healthcare provider about the best way to feed your baby during treatment with lurasidone hydrochloride tablets.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines

Lurasidone hydrochloride tablets and other medicines may affect each other causing possible serious side effects

Lurasidone hydrochloride tablets may affect the way other medicines work, and other medicines may affect how lurasidone

Your healthcare provider can tell you if it is safe to take Lurasidone hydrochloride tablets with your other medicines. Do not

start or stop any other medicines during treatment with lurasidone hydrochloride tablets without talking to your healthcare

Know the medicines you take. Keep a list of your medicines to show your healthcare provider and pharmacist when you get

Take lurasidone hydrochloride tablets exactly as your healthcare provider tells you to take it. Do not change the dose or

· If you take too many lurasidone hydrochloride tablets, call your healthcare provider or poison control center or go to the

Do not drive, operate heavy machinery, or do other dangerous activities until you know how lurasidone hydrochloride tablet affects you. Lurasidone hydrochloride tablets may make you drowsy.
 Avoid eating grapefruit or drinking grapefruit juice during treatment with lurasidone hydrochloride tablets. Grapefruit and

Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death. Neuroleptic malignant syndrome (NMS) a serious condition that can lead to death. Call your healthcare provider or

go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of

Uncontrolled body movements (tardive dyskinesia). Lurasidone hydrochloride tablets may cause movements that

you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking lurasidone hydrochloride tablets. Tardive dyskinesia may also start after you stop taking lurasidone hydrochloride

high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take

lurasidone hydrochloride tablets. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk

factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start and during treatment with lurasidone hydrochloride tablets.

Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with lurasidone

stop taking lurasidone hydrochloride tablets without first talking to your healthcare provider.

grapefruit juice may affect the amount of lurasidone hydrochloride tablets in your blood. Do not become too hot or dehydrated during treatment with lurasidone hydrochloride tablets

See "What is the most important information I should know about lurasidone hydrochloride tablets?

Take lurasidone hydrochloride tablets by mouth, with food (at least 350 calories).

• have or have had diabetes or high blood sugar, or have a family history of diabetes or high blood sugar.

voriconazole, mibefradil, rifampin, avasimibe, St. John's wort, phenytoin, or carbamazepine. Ask your healthcare

Lurasidone Hydrochlorid

Distributed by:

Cranbury, NJ 08512

Sun Pharmaceutical Industries Inc.

ous mental illnesses are the most important causes of suicidal thoughts and actions

Educate patients regarding appropriate care in avoiding overheating and dehydration [see Warnings and Precautions (5.13)].

Interference with Cognitive and Motor Performance Caution patients about performing activities requiring mental alertness, such as operating hazardous machinery or operating a

there is a potential for drug interactions [see Drug Interactions (7)].

Dispense with Medication Guide available at: https://www.sunpharma.com/usa/products

Lurasidone hydrochloride tablets may cause serious side effects, including:

needed, especially if you have concerns about symptoms.

What is the most important information I should know about lurasidone hydrochloride tablets

How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?

Manufactured by: Sun Pharmaceutical Industries Ltd.

SUN Survey No. 1012, Dadra-396 193, U.T. of D & NH and Daman & Diu, India.

abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremo

In the short-term, placebo-controlled schizophrenia and bipolar depression studies, data was objectively collected on the Simpson Angus Rating Scale (SAS) for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (BAS) for akathisia and the Abnorma Involuntary Movement Scale (AIMS) for dyskinesias.

Pediatric Patients (10 to 17 years)

In the 6-week placebo-controlled study of bipolar depression in pediatric patients 10 to 17 years, the incidence of EPS, excluding events related to akathisia, for lurasidone hydrochloride tablets-treated patients was similar in the lurasidone hydrochloride tablets 20 to 80 mg/day (3.4%) treatment group vs. placebo (3.5%); and the incidence of akathisia-related events for lurasidon ide tablets-treated patients was 2.9% vs. 3.5% for placebo-treated patients. Incidence of EPS by dose is provided in Table 28

Table 28: Incidence of EPS Compared to Placebo in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)

Adverse Event Term	Placebo (N=172) (%)	Lurasidone Hydrochloride Tablets 20 to 80 mg/day (N=175) (%)
All EPS events*	5	6
All EPS events, excluding Akathisia/Restlessness	4	3
Akathisia	4	3
Parkinsonism**	<1	<1
Dystonia***	1	<1
Salivary hypersecretion	<1	<1
Psychomotor hyperactivity	0	<1
Tardive Dyskinesia	<1	0

Note: Figures rounded to the nearest integer

EPS include adverse event terms: akathisia, cogwheel rigidity, dyskinesia, dystonia, hyperkinesia, joint stiffness, muscle rigidity, muscle spasms, musculoskeletal stiffness, oculogyric crisis, parkinsonism, tardive dyskinesia, and tremor * Parkinsonism includes adverse event terms: bradykinesia, drooling, extrapyramidal disorder, glabellar reflex abnormal,

hypokinesia, parkinsonism, and psychomotor retardation **Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

Schizophrenia

Adults The mean change from baseline for lurasidone hydrochloride tablets-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients, with the exception of the Barnes Akathisia Scale global score (lurasidone hydrochloride tablets, 0.1; placebo, 0.0). The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 14.4%; placebo, 7.1%), the SAS (lurasidone hydrochloride tablets, 5.0%; placebo, 2.3%) and the AIMS (lurasidone hydrochloride tablets, 7.4%; placebo, 5.8%).

Adolescents

The mean change from baseline for lurasidone hydrochloride tablets- treated patients with adolescent schizophrenia for the SAS BAS and AlloS was comparable to placebo-treated patients. The patients which advises the tablets of the SAS, greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 7.0%; placebo, 1.8%), the SAS (lurasidone hydrochloride tablets, 8.3%; placebo, 2.7%) and the AIMS (lurasidone hydrochloride tablets 2.8%; placebo, 0.9%)

Bipolar Depression

Adults Monotherapy The mean change from baseline for lurasidone hydrochloride tablets-treated adult patients for the SAS, BAS and AIMS was

comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 8.4%; placebo, 5.6%), the SAS (lurasidone hydrochloride tablets, 3.4%; placebo, 1.9%) and the AIMS (lurasidone hydrochloride tablets, 3.4%; placebo, 1.2%).

Adjunctive Therapy with Lithium or Valproate

The mean change from baseline for lurasidone hydrochloride tablets-treated adult patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 8.7%; placebo, 2.1%), the SAS (lurasidone hydrochloride tablets, 2.8%; placebo, 2.1%) and the AIMS (lurasidone hydrochloride tablets, 2.8%; placebo, 0.6%)

Pediatric Patients (10 to 17 years)

The mean change from baseline for lurasidone hydrochloride tablets- treated pediatric patients 10 to 17 years with bipolar depression for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 4.6%; placebo, 2.4%), the SAS (lurasidone hydrochloride tablets, 0.6%; placebo, 0%) and was the same for the AIMS (lurasidone hydrochloride tablets, 0%; placebo, 0%).

Dystonia

Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and vounder and groups.

Schizophrenia Adults

In the short-term, placebo-controlled schizophrenia clinical studies, dystonia occurred in 4.2% of lurasidone hydrochloride tablets treated subjects (0.0% lurasidone hydrochloride tablets 20 mg, 3.5% lurasidone hydrochloride tablets 40 mg, 4.5% lurasidone hydrochloride tablets 80 mg, 6.5% lurasidone hydrochloride tablets 120 mg and 2.5% lurasidone hydrochloride tablets 160 mg) compared to 0.8% of subjects receiving placebo. Seven subjects (0.5%, 7/1508) discontinued clinical trials due to dystonic events - four were receiving lurasidone hydrochloride tablets 80 mg/day and three were receiving lurasidone hydrochloride tablet 120 mg/day.

In the short-term, placebo-controlled, adolescent schizophrenia study, dystonia occurred in 1% of lurasidone hydrochloride tablets-treated patients (1% lurasidone hydrochloride tablets 40 mg and 1% lurasidone hydrochloride tablets 80 mg) compared to 0% of patients receiving placebo. No patients discontinued the clinical study due to dystonic events.

Bipolar Depressio

Adults Monotherapy

Adjunctive Therapy with Lithium or Valproate

clinical study due to dystonic events.

discontinued the clinical study due to dystonic events.

Blood and Lymphatic System Disorders: Infrequent: anemia

In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, dystonia occurred in 0.9% of lurasidone hydrochloride tablets-treated subjects (0.0% and 1.8% for lurasidone hydrochloride tablets 20 to 60 mg/day and lurasidone hydrochloride tablets 80 to 120 mg/day, respectively) compared to 0.0% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events

Pediatric Patients (10 to 17 years) In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, dystonia occurred in 0.6% of lurasidone hydrochloride tablets-treated patients compared to 1.2% of patients receiving placebo. No patients discontinued the

Following is a list of adverse reactions reported by adult patients treated with lurasidone hydrochloride tablets at multiple doses of \geq 20 mg once daily within the premarketing database of 2905 patients with schizophrenia. The reactions listed are those that could

be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions listed in Table 19 or those that appear elsewhere in the lurasidone hydrochloride tablets label are not included.

Reactions are further categorized by organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled studies appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in the studies appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 to 1/1000 patients (infrequent); and those occurr

Other Adverse Reactions Observed During the Premarketing Evaluation of Lurasidone Hydrochloride Tablets

Cardiac Disorders: Frequent: tachycardia; Infrequent: AV block 1st degree, angina pectoris, bradycardia

In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, dystonia occurred in 1.1% of lurasidone hydrochloride tablets-treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo. No subject resumed lurasidone hydrochloride tablets treatment for an additional two months.

10.2 Management of Overdosage

No specific antidotes for lorasidone hydrochloride tablets are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org).

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possibl arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of lurasidone hydrochloride tablets. Similarly the alpha-blocking properties of bretylium might be additive to those of lurasidone hydrochloride tablets, resulting in prob

Hypotension and circulatory collapse should be treated with appropriate measures. Epinephrine and dopamine should not be used, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension in the setting of lurasidone hydrochloride tablets-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medication should be administered

Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be

considered.

Ear and Labyrinth Disorders: Infrequent: vertigo Eye Disorders: Frequent: blurred vision Gastrointestinal Disorders: Frequent: abdominal pain, diarrhea; Infrequent: gastritis General Disorders and Administrative Site The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

Conditions: Rare: sudden death Investigations: Frequent: CPK increased

Metabolism and Nutritional System Disorders: Frequent: decreased appetite Musculoskeletal and Connective Tissue Disorders: Rare: rhabdomyolysis Nervous System Disorders: Infrequent: cerebrovascular accident, dysarthria Psychiatric Disorders: Infrequent: abnormal dreams, panic attack, sleep disorder Renal and Urinary Disorders: Infrequent: dysuria; Rare: renal failure

8.4 Pediatric Use

The safety and effectiveness of lurasidone hydrochloride tablets 40-mg/day and 80-mg/day for the treatment of schizophrenia in adolescents (13 to 17 years) was established in a 6-week, placebo-controlled clinical study in 326 adolescent patients [see Dosage and Administration (2.1), Adverse Reactions (6.1), and Clinical Studies (14.1)].

The safety and effectiveness of lurasidone hydrochloride tablets have not been established in pediatric patients less than 13 years of age with schizophrenia

The safety and effectiveness of lurasidone hydrochloride tablets 20 to 80 mg/day for the treatment of bipolar depression in pediatric Administration (2.2), Adverse Reactions (6.1), and Clinical Studies (14.2)].

The safety and effectiveness of lurasidone hydrochloride tablets have not been established in pediatric patients less than 10 years of

Irritability Associated with Autistic Disorder The effectiveness of lurasidone hydrochloride tablets in pediatric patients for the treatment of irritability associated with autistic

Efficacy was not demonstrated in a 6-week study evaluating lurasidone hydrochloride tablets 20 mg/day and 60 mg/day for the treatment of pediatric patients 6 to 17 years of age with irritability associated with autistic disorder diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria. The primary objective of the study as measured by improvement from Baseline in the irritability subscale of the Aberrant Behavior Checklist (ABC) at Endpoint (Week 6) was not met. A total of 149 patients were randomized to lurasidone hydrochloride tablets or placebo. Vomiting occurred at a higher rate than reported in other lurasidone hydrochloride tablets studies (4/49 or 8% for 20mg, 14/51 or 27% for 60mg, and 2/49 or 4% for placebo), particularly in children ages 6 to 12 (13 out of 18 patients on lurasidone hydrochloride tablets with vomiting).

In a long-term, open-label study that enrolled pediatric patients (age 6 to 17 years) with schizophrenia, bipolar depression, or autistic disorder from three short-term, placebo-controlled trials, 54% (378/701) received lurasidone for 104 weeks. There was one adverse event in this trial that was considered possibly drug-related and has not been reported in adults receiving lurasidone: a 10 year old male experienced a prolonged, painful erection, consistent with priapism, that led to treatment discontinuation

In this trial, the mean increase in height from open-label baseline to Week 104 was 4.94 cm. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of children and adolescents by comparisons to age- and sex-matched population standards. A z-score change <0.5 SD is considered not clinically significant. Ir this trial, the mean change in height z-score from open-label baseline to Week 104 was +0.05 SD, indicating minimal deviation from the normal growth curve.

Juvenile animal studies

Adverse effects were seen on growth, physical and neurobehavioral development at doses as low as 0.2 times the MRHD based or mg/m². Lurasidone was orally administered to rats from postnatal days 21 through 91 (this period corresponds to childhood adolescence, and young adulthood in humans) at doses of 3, 30, and 150 (males) or 300 (females) mg/kg/day which are 0.2 to 10 times (males) and 20 times (females) the maximum recommended adult human dose (MRHD) of 160 mg/day based on mg/m². The adverse effects included dose-dependent decreases in femoral length, bone mineral content, body and brain weights at 2 times the MRHD in both sexes, and motor hyperactivity at 0.2 and 2 times the MRHD in both sexes based on mg/m². In females, there was a delay in attainment of sexual maturity at 2 times the MRHD, associated with decreased serum estradiol. Mortality occurred in both sexes during early post-weaning period and some of the male weanlings died after only 4 treatments at doses as low as 2 times the MRHD based on mg/m². Histopathological findings included increased colloid in the thyroids and inflammation of the prostate in males at 10 times MRHD based on mo/m² and mammary oland hyperplasia, increased vaginal mucification, and increased ovariar arteric follicles at does as low as 0.2 times the MRHD based on mg/m². Some of these findings were attributed to transiently elevated serum prolactin which was seen in both sexes at all does. However, there were no changes at any dose level in reproductive parameters (fertility, conception indices, spermatogenesis, estrous cycle, gestation length, parturition, number of pups born). The no effect dose for neurobehavioral changes in males is 0.2 times the MRHD based on mg/m² and could not be determined in females. The no effect dose for growth and physical development in both sexes is 0.2 times the MRHD based on

8.5 Geriatric Use

Clinical studies with lurasidone hydrochloride tablets did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients. In elderly patients with psychosis (65 to 85), lurasidone hydrochloride tablets concentrations (20 mg/day) were similar to those in young subjects. It is unknown whether dose adjustment ssary on the basis of age alone.

Elderly patients with dementia-related psychosis treated with lurasidone hydrochloride tablets are at an increased risk of death ared to placebo. Lurasidone hydrochloride tablet is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning, Warnings and Precautions (5.1, 5.3)]

8.6 Renal Impairment

Reduce the maximum recommended dosage in patients with moderate or severe renal impairment (CLcr < 50 mL/minute). Patients with impaired renal function (CLcr < 50 mL/minute) had higher exposure to lurasidone than patients with normal renal function [see *Clinical Pharmacology* (12.3)]. Greater exposure may increase the risk of lurasidone hydrochloride tablets-associated adverse reactions [see Dosage and Administration (2.4)].

Hepatic Impairment

Reduce the maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh score \geq 7). Patients with moderate to severe hepatic impairment (Child-Pugh score \geq 7) generally had higher exposure to lurasidone bursilone tagin source \geq 7) generally had higher exposure to lurasidone the patients with normal hepatic function [see Clinical Pharmacology (12.3)]. Greater exposure may increase the risk of lurasidone hydrochloride tablets-associated adverse reactions [see Dosage and Administration (2.5)].

8.8 Other Specific Population

No dosage adjustment for lurasidone hydrochloride tablets is required on the basis of a patient's sex, race, or smoking status [see Clinical Pharmacology (12.3)].

DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance idone hydrochloride is not a controlled substance


9.2 Abuse

Lurasidone hydrochloride tablets have not been systematically studied in humans for its potential for abuse or physical dependence Location in your monte cause of a recent systematically source of monte source of the be misused, diverted and/or abused once it is marketed. Patients should be evaluated carefully for a history of drug abuse, and such patients should be observed carefully for signs of lurasidone hydrochloride tablets misuse or abuse (e.g., develo drug-seeking behavior, increases in dose)

OVERDOSAGE 10.1 Human Experience

In premarketing clinical studies, accidental or intentional overdosage of lurasidone hydrochloride tablets were identified in one patient who ingested an estimated 560 mg of lurasidone hydrochloride tablets. This patient recovered without sequelae. This patient

Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives.



NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis: Lurasione increased incidences of malignant mammary gland tumors and pituitary gland adenomas in female mice orally dosed with 30, 100, 300, or 650 mg/kg/day. The lowest dose produced plasma levels (AUC) approximately equal to those in humans receiving the MRHD of 160 mg/day. No increases in tumors were seen in male mice up to the highest dose tested,

H•---

one increased the incidence of mammary gland carcinomas in female rats orally dosed at 12 and 36 mg/kg/day: the low dose; 3 mg/kg/day is the no-effect dose which produced plasma levels (AUC) 0.4 times those in humans receiving the MRHD. No increases in tumors were seen in male rats up to the highest dose tested, which produced plasma levels (AUC) 6 times those in numans receiving the MBHD

Proliferative and/or neoplastic changes in the mammary and pituitary glands of rodents have been observed following chronic administration of antipsychotic drugs and are considered to be prolactin-mediated [see Warnings and Precautions (5.7]

Mutagenesis: Lurasidone did not cause mutation or chromosomal aberration when tested in vitro and in vivo test battery. Lurasidone was negative in the Ames gene mutation test, the Chinese Hamster Lung (CHL) cells, and in the in vivo mouse bone marrow micronucleus test up to 2.000 mg/kg which is 61 times the MRHD of 160 mg/day based on mg/m² body surface area.

irment of Fertility: Estrus cycle irregularities were seen in rats orally administered lurasidone at 1.5, 15 and 150 mg/kg/day for 15 consecutive days prior to mating, during the mating period, and through gestation day 7. No effect was seen at the lowest dose of 0.1 mg/kg which is approximately 0.006 times the MRHD of 160 mg/day based on mg/m². Fertility was reduced only at the highest dose, which was reversible after a 14 day drug-free period. The no-effect dose for reduced fertility was approximately equal to the MRHD based on mg/m

Lurasidone had no effect on fertility in male rats treated orally for 64 consecutive days prior to mating and during the mating period at doses up to 9 times the MRHD based on mg/m

CLINICAL STUDIES 14

14.1 Schizophrenia

The efficacy of lurasidone hydrochloride tablets for the treatment of schizophrenia was established in five short-term (6-week) lled studies in adult patients (mean age of 38.4 years, range 18 to 72) who met DSM-IV criteria for sc active-control arm (olanzapine or quetiapine extended-release) was included in two studies to assess assay sensitivity.

- Several instruments were used for assessing psychiatric signs and symptoms in these studies:
 1. Positive and Negative Syndrome Scale (PANSS), is a multi-item inventory of general psychopathology used to evaluate the
 effects of drug treatment in schizophrenia. PANSS total scores may range from 30 to 210. Brief Psychiatric Rating Scale derived (BPRSd), derived from the PANSS, is a multi-item inventory primarily focusing on positive
- spring the second 18 to 126.
- The Clinical Global Impression severity scale (CGI-S) is a clinician-rated scale that measures the subject's current illness state on a 1- to 7-point scale.

The endpoint associated with each instrument is change from baseline in the total score to the end of week 6. These changes are then compared to placebo changes for the drug and control groups.

The results of the studies follow

- Study 1: In a 6-week, placebo-controlled trial (N=145) involving two fixed doses of lurasidone hydrochloride tablets (40 or 120 mg/day), both doses of lurasidone hydrochloride tablets at Endpoint were superior to placebo on the BPRSd total score, and the CGI-S. 2
- Study 2: In a 6-week, placebo-controlled trial (N=180) involving a fixed dose of lurasidone hydrochloride tablets (80 mg/day). unasidone hydrochloride tablets at Endpoint was superior to placebo on the BPRS of tables, and the GGI-S. Study 3: In a 6-week, placebo- and active-controlled trial (N=473) involving two fixed doses of lurasidone hydrochloride tablets
- (40 or 120 mg/day) and an active control (olanzapine), both lurasidone hydrochloride tablets doses and the active control at Endpoint were superior to placebo on the PANSS total score, and the CGI-S. Study 4: In a 6-week, placebo-controlled trial (N=489) involving three fixed doses of lurasidone hydrochloride tablets (40, 80 or 120 mg/day), only the 80 mg/day dose of lurasidone hydrochloride tablets at Endpoint was superior to placebo on the PANSS
- total score, and the CGI-S.
- Study 5: In a 6-week, placebo- and active-controlled trial (N=482) involving two fixed doses of lurasidone hydrochloride tablets (80 or 160 mg/day) and an active control (quetiapine extended-release), both lurasidone hydrochloride tablets doses and the active control at Endpoint were superior to placebo on the PANSS total score, and the CGI-S.

Thus, the efficacy of lurasidone hydrochloride tablets at doses of 40, 80, 120 and 160 mg/day has been established (Table 35).

acy Results for Studies in Adult Patients with Schizonh

			Primary Efficacy Measure:	BPRSd
Study	Treatment Group	Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo-subtracted Difference [®] (95% Cl)
	Lurasidone hydrochloride tablets (40 mg/day)*	54.2 (8.8)	-9.4 (1.6)	-5.6 (-9.8, -1.4)
1	Lurasidone hydrochloride tablets (120 mg/day)*	52.7 (7.6)	-11.0 (1.6)	-6.7 (-11.0,-2.5)
	Placebo	54.7 (8.1)	-3.8 (1.6)	-
2	Lurasidone hydrochloride tablets (80 mg/day)*	55.1 (6.0)	-8.9 (1.3)	-4.7 (-8.3, -1.1)
Placebo		56.1 (6.8)	-4.2 (1.4)	-
			Primary Efficacy Measure:	PANSS
	Lurasidone hydrochloride tablets (40 mg/day)*	96.6 (10.7)	-25.7 (2.0)	-9.7 (-15.3, -4.1)
3	Lurasidone hydrochloride tablets (120 mg/day)*	97.9 (11.3)	-23.6 (2.1)	-7.5 (-13.4, -1.7)
	Olanzapine (15 mg/day)*b	96.3 (12.2)	-28.7 (1.9)	-12.6 (-18.2,-7.9)
	Placebo	95.8 (10.8)	-16.0 (2.1)	-
	Lurasidone hydrochloride tablets (40 mg/day)	96.5 (11.5)	-19.2 (1.7)	-2.1 (-7.0, 2.8)
4	Lurasidone hydrochloride tablets (80 mg/day)*	96.0 (10.8)	-23.4 (1.8)	-6.4 (-11.3, -1.5)
	Lurasidone hydrochloride tablets (120 mg/day)	96.0 (9.7)	-20.5 (1.8)	-3.5 (-8.4, 1.4)
	Placebo	96.8 (11.1)	-17.0 (1.8)	-
	Lurasidone hydrochloride tablets (80 mg/day)*	97.7 (9.7)	-22.2 (1.8)	-11.9 (-16.9, -6.9)
5	Lurasidone hydrochloride tablets (160 mg/day)*	97.5 (11.8)	-26.5 (1.8)	-16.2 (-21.2, -11.2)
	Quetiapine Extended-release (600 mg/day)*b	97.7 (10.2)	-27.8 (1.8)	-17.5 (-22.5,-12.4)
	Placebo	96.6 (10.2)	-10.3 (1.8)	-

Reproductive System and Breast Disorders: Infrequent: amenormhea, dysmenormhea; Rare: breast enlargement, breast pain, galactorrhea, erectile dysfunction, priapism Skin and Subcutaneous Tissue Disorders: Frequent: rash, pruritus; Rare: angioedema Vascular Disorders: Frequent:

Clinical Laboratory Changes

patients (rare).

Adults Serum Creatinine: In short-term, placebo-controlled trials, the mean change from Baseline in serum creatinine was +0.05 mg/dL for lurasidone hydrochloride tablets-treated patients compared to +0.02 mg/dL for placebo-treated patients. A creatinine shift from for lurasidone hydrochloride tablets-treated patients compared to +0.02 mg/dL for placebo-treated patients. A creatinine shift from threshold for high creatinine value varied from > 0.79 to > 1.3 mg/dL based on the centralized laboratory definition for each stud

Table 29: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in Adult Schizophrenia Studies

Laboratory Parameter	Placebo (N=708)	Lurasidone Hydrochloride Tablets 20 mg/day (N=71)	Lurasidone Hydrochloride Tablets 40 mg/day (N=487)	Lurasidone Hydrochloride Tablets 80 mg/day (N=538)	Lurasidone Hydrochloride Tablets 120 mg/day (N=291)	Lurasidone Hydrochloride Tablets 160 mg/day (N=121)
Serum Creatinine Elevated	2%	1%	2%	2%	5%	7%

Adolescents

Serum Creatinine: In the short-term, placebo-controlled, adolescent schizophrenia study, the mean change from Baseline in serum creatinine was -0.009 mo/dL for lurasidone hydrochloride tablets-treated patients compared to +0.017 mo/dL for placebo-treated patients. A creatinine shift from normal to high (based on the centralized laboratory definition) occurred in 7.2% (14/194) of sidone hydrochloride tablets-treated patients and 2.9% (3/103) on placebo (Table 30)

Table 30: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adolescent Schizonhrenia Study

Laboratory Parameter	Placebo (N=103)	Lurasidone Hydrochloride Tablets 40 mg/day (N=97)	Lurasidone Hydrochloride Tablets 80 mg/day (N=97)
Serum Creatinine Elevated	2.9%	7.2%	7.2%

Bipolar Depression

Adults Monotherapy

Serum Creatinine: In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the mean change from Baseline in serum creating was +0.01 mg/dL for lurasidone hydrochloride tablets-treated patients compared to -0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 2.8% (9/322) of lurasidone hydrochloride tablets-treated patients and 0.6% (1/162) on placebo (Table 31).

Table 31: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adult Monotherapy Bipola Depression Study

Laboratory Parameter	Placebo (N=168)	Lurasidone Hydrochloride Tablets 20 to 60 mg/day (N=164)	Lurasidone Hydrochloride Tablets 80 to 120 mg/day (N=167)
Serum Creatinine Elevated	<1%	2%	4%

Adjunctive Therapy with Lithium or Valproate

Serum Creatinine: In adult short-term, placebo-controlled premarketing adjunctive studies for bipolar depression, the mean change from Baseline in serum creatinine was +0.04 mg/dL for lurasidone hydrochloride tablets-treated patients compared to -0.01 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 4.3% (15/360) of lurasidone hydrochloride tablets-treated patients and 1.6% (5/334) on placebo (Table 32).

Table 32: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adult Adjunctive Therapy Bipolar ression Studie:

Laboratory Parameter	Placebo (N=334)	Lurasidone Hydrochloride Tablets 20 to 120 mg/day (N=360)
Serum Creatinine Elevated	2%	4%

Pediatric Patients (10 to 17 years)

Serum Creatinine: In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, the mean change from Baseline in serum creatinine was +0.021 mg/dL for lurasidone hydrochloride tablets-treated patients compared to +0.009 mg/dL for placebo-treated patients. A creatinine shift from normal to high (based on the centralized laboratory definition) occurred in 6.7% (11/163) of lurasidone hydrochloride tablets-treated patients and 4.5% (7/155) on placebo (Table 33)

Its chemical name is $(3aR, 4S, 7R, 7aS)-2-\{(1R, 2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]$ cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride. Its molecular formula is C_{ar}H_{ar}N₂O₂S+HCl and Carbon explored and the second its molecular weight is 529.14.

The chemical structure is

Lurasidone hydrochloride is a white to off-white powder. It is very slightly soluble in water, practically insoluble or insoluble in 0.1 N HCI, slightly soluble in ethanol, sparingly soluble in methanol, practically insoluble or insoluble in toluene and very slightly soluble in

Lurasidone hydrochloride tablets are intended for oral administration only. Each tablet contains 20 mg, 40 mg, 60 mg, 80 mg, or 120 mg of lurasidone hydrochloride.

Inactive ingredients are maniful alonic acid pregelatinized corn starch croscarmellose sodium colloidal silicon dioxide magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol and carnauba wax. The 80 mg tablets also contain yellov iron oxide, FD&C Blue#1 aluminum lake and black iron oxide.

CLINICAL PHARMACOLOGY 12 CLINICAL PHARMACO 12.1 Mechanism of Action

The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in phrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin Typ 2 (5HT2A) receptor antagonism.

12.2 Pharmacodynamics

Lurasidone is an antagonist with high affinity binding at the dopamine D2 receptors (Ki of 1 nM) and the serotonin 5-HT2A (Ki of 0.5 nM) and 5-HT7 (Ki of 0.5 nM) receptors. It also binds with moderate affinity to the human α 2C adrenergic receptors (Ki of 11 nM) is a partial aponist at serotonin 5-HT1A (Ki of 6.4 nM) recentors, and is an antagonist at the α 2A adrenergic recentors. (Ki of 41 nM). Lurasidone exhibits little or no affinity for histamine H1 and muscarinic M1 receptors (IC50 > 1,000 nM)

ECGChanges The effects of lurasidone hydrochloride tablets on the QTc interval were evaluated in a randomized, double-blind, multiple-dose, parallel-dedicated thorough QT study in 43 patients with schizophrenia or schizoaffective disorder, who were treated with lurasidone hydrochloride tablets doses of 120 mg daily, 600 mg daily and completed the study. The maximum mean (upper 1-sided, 95% CI) increase in baseline-adjusted OTc intervals based on individual correction method (OTcl) was 7.5 (11.7) ms and 4.6 (9.5) ms, for the 120 mg and 600 mg dose groups respectively, observed at 2 to 4 hours after dosing. In this study, there was no app dose (exposure)-response relationship.

In short-term, placebo-controlled studies in schizophrenia and bipolar depression, no post-baseline QT prolongations exceeding 500 msec were reported in patients treated with lurasidone hydrochloride tablets or placebo

12.3 Pharmacokinetics

The activity of lurasidone hydrochloride tablets is primarily due to the parent drug. The pharmacokinetics of lurasidon hydrochloride tablets is dose-proportional within a total daily dose range of 20 mg to 160 mg. Steady-state concentrations of lurasidone hydrochloride tablets are reached within 7 days of starting lurasidone hydrochloride tablets.

Following administration of 40 mg of lurasidone hydrochloride tablets, the mean (%CV) elimination half-life was 18 (7) hours.

Absorption and Distribution: Lurasidone hydrochloride tablets are absorbed and reaches peak serum concentrations in Australia and Distribution. Curastione hydrochionide tauters are austroled and reactines peak serium concentrations in approximately 1 to 3 hours. It is estimated that 9 to 19% of an administrated dose is absorbed. Following administration of 40 mg of lurasidone hydrochloride tablets, the mean (%CV) apparent volume of distribution was 6173 (17.2) L. Lurasidone hydrochloride tablets are highly bound (\sim 99%) to serum proteins

In a food effect study, lurasidone hydrochloride tablets mean Cmax and AUC were about 3-times and 2-times, respectively, when administered with food compared to the levels observed under fasting conditions. Lurasidone hydrochloride tablets exposure was not affected as meal size was increased from 350 to 1000 calories and was independent of meal fat content [see Dosage and

In clinical studies, establishing the safety and efficacy of lurasidone hydrochloride tablets, patients were instructed to take their daily dose with food [see Dosage and Administration (2.3)]

Metabolism and Elimination: Lurasidone hydrochloride tablets are metabolized mainly via CYP3A4. The major biotransformation pathways are oxidative M-dealkylation, hydroxylation of norbornane ring, and S-oxidation. Lurasidone hydrochloride tablets are metabolized into two active metabolites (ID-14283 and ID-14326) and two major non-active metabolites (ID-20220). ID-20220). Based on *in vitro* studies, lurasidone hydrochloride tablet is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C9, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes. Because lurasidone hydrochloride is not a substrate for cokinetics of lurasidone hydrochloride tablets CYP1A2, smoking is not expected to have an effect on the pharm

Transporter proteins: In vitro studies suggest lurasidone hydrochloride is not a substrate of OATP1B1 or OATP1B3, however, is probably a substrate of P-gp and BCRP. *In vitro* studies indicate that lurasidone hydrochloride is not expected to inhibit transporters OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2-K and BSEP at clinically relevant concentrations. Lurasidone hydrochloride tablets are not a clinically significant inhibitor of P-gp. However, it may inhibit BCRP.

Total excretion of radioactivity in urine and feces combined was approximately 89%, with about 80% recovered in feces and 9% ed in urine, after a single dose of [14C]-labeled lurasidone hydrochloride tab

Following administration of 40 mg of lurasidone hydrochloride tablets, the mean (%CV) apparent clearance was 3902 (18.0) mL/min

The primary rating instrument used to assess psychiatric signs and symptoms was the PANSS. The key secondary instrument was the CGI-S

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple

Examination of population subgroups based on age (there were few patients over 65), gender and race did not reveal any clear

Autorescense (13 of 17 years) The efficacy of lurasidone hydrochloride tablets, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adolescents (13 to 17 years) who met DSM-IV-TR criteria for schizophrenia (N=326). Patients were

For both dose groups, lurasidone hydrochloride tablets were superior to placebo in reduction of PANSS and CGI-S scores at Week 6. On average, the 80 mg/day dose did not provide additional benefit compared to the 40 mg/day dose.

The primary efficacy results are provided in Table 36.

Included for assay sensitivity. Doses statistically significantly superior to placebo.

evidence of differential responsiveness.

Adolescents (13 to 17 years)

Table 36: Primary Efficacy Results (PANSS Total Score) for the Adolescent Schizophrenia Study

randomized to one of two fixed-doses of lurasidone hydrochloride tablets (40 or 80 mg/day) or placebo

Difference (drug minus placebo) in least-squares mean change from baseline.

Treatment Group	Primary Efficacy Measure: PANSS				
	Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo-subtracted Difference [®] (95% Cl)		
Lurasidone hydrochloride tablets (40 mg/day)*	94.5 (10.97)	-18.6 (1.59)	-8.0 (-12.4, -3.7)		
Lurasidone hydrochloride tablets (80 mg/day)*	94.0 (11.12)	-18.3 (1.60)	-7.7 (-12.1, -3.4)		
Placebo	92.8 (11.08)	-10.5 (1.59)	-		

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple

Difference (drug minus placebo) in least-squares mean change from baseline. Doses statistically significantly superior to placebo

14.2 Depressive Episodes Associated with Bipolar I Disorde

Adults Monotherapy

comparisons.

The efficacy of lurasidone hydrochloride tablets, as monotherapy, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adult patients (mean age of 41.5 years, range 18 to 74) who met DSM-IV-TR criteria for major depressive episodes associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=485) Patients were randomized to one of two flexible-dose ranges of lurasidone hydrochloride tablets (20 to 60 mg/day, or 80 to 120 mg/day) or placebo.

The primary rating instrument used to assess depressive symptoms in this study was the Montgomery-Asherg Depression Rating Scale (MADRS), a 10-tem clinician-rated scale with total scores ranging from 0 (no depressive features) to 60 (maximum score). The primary endpoint was the change from baseline in MADRS score at Week 6. The key secondary instrument was the Clinical ession-Bipolar-Severity of Illness scale (CGI-BP-S), a clinician-rated scale that measures the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness sev

For both dose groups, lurasidone hydrochloride tablets were superior to placebo in reduction of MADRS and CGI-BP-S scores at Week 6. The primary efficacy results are provided in Table 37. The high dose range (80 to 120 mg per day) did not provide additional efficacy on average, compared to the low dose range (20 to 60 mg per day).

Adjunctive Therapy with Lithium or Valproate

The efficacy of lurasidone hydrochloride tablets, as an adjunctive therapy with lithium or valproate, was established in a 6-week multicenter, randomized, double-blind, placebo-controlled study of adult patients (mean age of 41.7 years, range 18 to 72) who met DSM-IV-TR criteria for major depressive episodes associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=340). Patients who remained symptomatic after treatment with lithium or valproate were randomized to bly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo

The primary rating instrument used to assess depressive symptoms in this study was the MADRS. The primary endpoint was the change from baseline in MADRS score at Week 6. The key secondary instrument was the CGI-BP-S sca

Lurasidone hydrochloride tablets were superior to placebo in reduction of MADRS and CGI-BP-S scores at Week 6, as an adjunctive therapy with lithium or valproate (Table 37)

Table 37: Primary Efficacy Results for Adult Studies in Depressive Episodes Associated with Bipolar I Disorder (MADRS Scores)

	Treatment Group	Primary Efficacy Measure: MADRS		
Study		Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo-subtracted Difference ^a (95% CI)
Monotherapy study	Lurasidone hydrochloride tablets (20 to 60 mg/day)*	30.3 (5.0)	-15.4 (0.8)	-4.6 (-6.9, -2.3)
	Lurasidone hydrochloride tablets (80 to 120 mg/day)*	30.6 (4.9)	-15.4 (0.8)	-4.6 (-6.9, -2.3)
	Placebo	30.5 (5.0)	-10.7 (0.8)	-
Adjunctive Therapy study	Lurasidone hydrochloride tablets (20 to 120 mg/day)* + lithium or valproate	30.6 (5.3)	-17.1 (0.9)	-3.6 (-6.0, -1.1)
-	Placebo + lithium or valproate	30.8 (4.8)	-13.5 (0.9)	-

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple

- Difference (drug minus placebo) in least-squares mean change from baseline.
- Treatment group statistically significantly superior to placebo

Pediatric Patients (10 to 17 years)

The efficacy of lurasidone hydrochloride tablets were established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of pediatric patients (10 to 17 years) who met DSM-5 criteria for a major depressive episode associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=343). Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 80 mg/day or placebo. At the end of the clinical study, most patients (67%) received 20 mg/day or 40 mg/day.

The primary rating scale used to assess depressive symptoms in this study was the Children's Depression Rating Scale. Revised (CDRS-R) total score. The CDRS-R is a 17-item clinician-rated scale with total scores ranging from 17 to 113. The primary endpoint was the change from baseline in CDRS-R score at Week 6. The key secondary endpoint was the change from baseline in CGIBP-S depression score.

increased fat levels (cholesterol and triglycerides) in your blood.

- weight gain. You and your healthcare provider should check your weight regularly during treatment with lurasidone hydrochloride tablets.
- Increased prolactin levels in your blood (hyperprolactinemia). Your healthcare provider may do blood tests to check your prolactin levels during treatment with lurasidone hydrochloride tablets. Tell your healthcare provider if you have any of the following signs and symptoms of hyperprolactinemia:
- Females:
- absence of your menstrual cycle
- secretion of breast milk when you are not breastfeeding
- Males: problems getting or maintaining an erection (erectile dysfunction)
- enlargement of breasts (gynecomastia)
- Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with

Decreased blood pressure (orthostatic hypotension). You may feel lightheaded or faint when you rise too quickly from a sitting or lying position. Falls. Lurasidone hydrochloride tablets may make you sleepy or dizzy, may cause a decrease in your blood pressure when

changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries. Seizures (convulsio

· Problems controlling your body temperature so that you feel too warm. See "What should I avoid while taking idone hydrochloride tablets

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lurasidone

hydrochloride tablets for a condition for which it was not prescribed. Do not give lurasidone hydrochloride tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about lurasidone hydrochloride tablets that is written for health professionals.

Inactive ingredients: mannitol, alginic acid, pregelatinized corn starch, croscarmellose sodium, colloidal silicon dioxide magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol and carnauba wax. The 80 mg tablets also contain yellow iron oxide, FD&C Blue#1 aluminum lake and black iron oxide.

Distributed by:

Cranbury, NJ 08512

Sun Pharmaceutical Industries, Inc.

Bev. 524

- Mania or hypomania (manic episodes) in people with a history of bipolar disorder. Symptoms may include:
- greatly increased energy severe problems sleeping
- racing thoughts reckless behavio
- unusually grand ideas
- excessive happiness or irritability
- talking more or faster than usua

Difficulty swallowing

The most common side effects of lurasidone hydrochloride tablets include Adults with schizophrenia:

- sleepiness or drowsiness
- restlessness and feeling like you need to move around (akathisia)
- difficulty moving, slow movements, muscle stiffness, or tremor

restlessness and feeling like you need to move around (akathisia)

difficulty moving, slow movements, muscle stiffness, or tremor

restlessness and feeling like you need to move around (akathisia) difficulty moving, slow movements, muscle stiffness, or tremor

Children 10 to 17 years of age with bipolar depression

How should I store lurasidone hydrochloride tablets?

Store lurasidone hydrochloride tablets at 20° to 25°C (68° to 77°F).

What are the ingredients in lurasidone hydrochloride tablets?

Active ingredient: lurasidone hydrochlo

Manufactured by:

Sun Pharmaceutical Industries Limited

SUN PHABMA U.T. of D & NH and Daman & Diu, India.

For more information, call 1-800-818-4555

Keep lurasidone hydrochloride tablets and all medicines out of the reach of children.

General information about the safe and effective use of lurasidone hydrochloride tablets.

Dispense with Medication Guide available at: https://www.sunpharma.com/usa/products

This Medication Guide has been approved by the U.S. Food and Drug Administration

Children 13 to 17 years of age with schizophrenia:

sleepiness or drowsines

Adults with bipolar depression:

sleepiness or drowsiness

nausea

nausea

weight gain problems sleeping (insomnia)

runny nose